

Date: September 7, 1999

514 Filed PCT/PTO 9/7/99 SEP 8 1999

**TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 USC 371**

International Application No.: PCT/AU98/00145  
International Filing Date: 6 March 1998  
Priority Date Claimed: 7 March 1997  
Title of Invention: LEPTOSPIRA PATHOGENS  
Applicant(s) for DO/EO/US: Roderick J. Chappel

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. (X) This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. (X) This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).
3. (X) A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
4. (X) A copy of the International Application as filed (35 USC 371(c)(2))
  - a) ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b) ☒ has been transmitted by the International Bureau.
  - c) ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
5. (X) Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))
  - a) ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b) ☐ have been transmitted by the International Bureau.
  - c) ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d) ☒ have not been made and will not be made.
6. (X) A copy of the International Preliminary Examination Report with annexes thereto, including amendments made under PCT Article 34.

**Items below concern other document(s) or information included:**

7. (X) A FIRST preliminary amendment with attached Abstract.
8. (X) International Application as published. Please note that through an error made by the International Bureau, this publication omits the drawing pages. The Australian Receiving Office has asked the International Bureau to republish the application with the drawings.
9. (X) A copy of the drawings which were included in the International Application as filed.
10. (X) A copy of the International Search Report.
11. (X) PCT Form PCT/IB/308.

U.S. Application No.

International Application No.  
PCT/AU98/00145

Attorney Docket No.  
DAVIE79.001APC

Date: September 7, 1999

Page 2

12. (X) A return prepaid postcard.
13. (X) The following fees are submitted:

				FEES
BASIC FEE				\$970
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	122 - 20 =	102 ×	\$18	\$1836
Independent Claims	2 - 3 =	0 ×	\$78	\$0
Multiple dependent claims(s) (if applicable)			\$260	\$0
TOTAL OF ABOVE CALCULATIONS				\$2806

14. (X) A check in the amount of \$970 to cover the basic fee only is enclosed. The fees for any excess claims fees will be paid in response to a Notice of Missing Requirements.
15. (X) The fee for later submission of the signed oath or declaration set forth in 37 CFR 1.492(e) will be paid upon submission of the declaration.
16. (X) The Commissioner is hereby authorized to charge only those additional fees which may be required to avoid abandonment of the application, or credit any overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

KNOBBE, MARTENS, OLSON & BEAR, LLP  
Customer No. 20,995

*Daniel Altman*  
Signature

Daniel E. Altman  
Printed Name

34,115  
Registration Number

E:\DOCS\DEA\DEA-1619.DOC  
090799

66227-92808260

DAVIE79.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Chappel, R. et al.	)	Group Art Unit Unknown
			)	
Int'l			)	
Appl. No.	:	PCT/AU98/00145	)	
			)	
Int'l Filing			)	
Date	:	March 6, 1999	)	
			)	
For	:	LEPTOSPIRA PATHOGENS	)	
			)	
Examiner	:	Unknown	)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Preliminary to examination on the merits, please amend the above-identified U.S. National Phase application as follows:

IN THE SPECIFICATION:

On page 1 of the Specification, after the Title of the Invention and before the Field of the Invention statement starting on line 3, please insert --This is the U.S. National Phase under 35 U.S.C. § 371 of International Application PCT/AU98/00145, filed March 6, 1999, which claims priority of Australian Patent Application P05494/97, filed March 7, 1997.--.

On page 81 before Claim 1, please delete the word "CLAIMS" and substitute therefor --WHAT IS CLAIMED IS--.

On page 9, line 8, after the sequence "5'-TGTTGGA-3'" and before the word "or", please insert -- (SEQ ID NO:4) --.

On page 9, line 8, after the sequence "5'-TTTGATA-3'" and before the word "or", please insert -- (SEQ ID NO:5) --.

On page 9, line 9, after the sequence "5'-TGTTGGA(N)<sub>8</sub>TTTGATA-3'" and before the word "or", please insert -- (SEQ ID NO:6) --.

On page 9, line 16, after the "3'" and before the word "or", please insert -- (SEQ ID NO:7) --.

On page 17, line 12, after the sequence "5'-TGTTGGA-3'" and before the word "or", please insert -- (SEQ ID NO:4) --.

On page 17, line 12, after the sequence "5'-TTTGATA-3'" and before the word "or", please insert -- (SEQ ID NO:5) --.

On page 17, line 13, after the sequence "5'-TGTTGGA(N)<sub>8</sub>TTTGATA-3'" and before the word "or", please insert -- (SEQ ID NO:6) --.

On page 17, line 19, after the sequence "5'-TGTTGGATCACAAGATTTGATA-3'", please insert -- (SEQ ID NO:7) --.

On page 52, line 6, after the sequence "CATGGATCCAGAGTTTGATCMTGGCTCAG", please insert -- (SEQ ID NO:16) --.

On page 52, line 7, after the sequence "GTGCCAGCMGCCGCGG", please insert -- (SEQ ID NO:17) --.

On page 52, line 8, after the sequence "AAACTYAAAKGAATTGACGG", please insert -- (SEQ ID NO:18) --.

On page 52, line 9, after the sequence "CGGCGCGTCTTAAACATG", please insert -- (SEQ ID NO:19) --.

On page 52, line 10, after the sequence "CAAGTCAAGCGGAGTAGCAA", please insert -- (SEQ ID NO:20) --.

On page 52, line 11, after the sequence "ACGGGCGGTGTGTRC", please insert -- (SEQ ID NO:21) --.

On page 52, line 12, after the sequence "GGGTTGCGCTCGTTG", please insert -- (SEQ ID NO:22) --.

On page 52, line 13, after the sequence "TTCACCGCTACACCTGGAA", please insert -- (SEQ ID NO:3) --.

On page 52, line 14, after the sequence "GWATTACCGCGGCKGCTG", please insert -- (SEQ ID NO:23) --.

On page 52, line 15, after the sequence "ACCATCATCACATYGCTGC", please insert -- (SEQ ID NO:24) --.

On page 52, line 16, after the sequence "TTCCCCCATTGAGCAAGATT", please insert -- (SEQ ID NO:25) --.

On page 52, line 17, after the sequence "TTATTTTCCCTGCTTAACTGAAC", please insert -- (SEQ ID NO:26) --.

**IN THE CLAIMS:**

**Please delete Claim 43.**

**Please amend the claims as follows:**

4. (Amended) The isolated pathogenic *Leptospira* bacterium according to claim[s] 2 [or 3], wherein said bacterium is capable of growing at temperatures in the range from about 13°C to about 37°C.

5. (Amended) The isolated pathogenic *Leptospira* bacterium according to [any one of] Claim[s] 1 [to 4], wherein said bacterium is a pathogen which is capable of infecting a mammal selected from the group consisting of: human [or a], livestock animal [or a], and companion animal [selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats].

9. (Amended) The isolated pathogenic *Leptospira* bacterium according to [any one of] Claim[s] 5 [to 8], wherein said bacterium is capable of producing the symptoms of leptospirosis in a human or other animal which it infects.

10. (Amended) The isolated pathogenic *Leptospira* bacterium according to [any one of] Claim[s] 1 [to 8], wherein said bacterium is capable of inducing reproductive disease.

15. (Amended) The isolated pathogenic *Leptospira* bacterium according to [any one of] Claim[s] 1 [to 14], wherein said bacterium further contains nucleic acid which is at least about 80% identical to the nucleotide sequence [set forth in any one] selected from the group consisting of SEQ ID NOs: 1-2, [or] 4-7, [or a homologue, analogue or derivative thereof comprising at least 15 contiguous nucleotides which are at least about 80% identical to the nucleotide sequence set forth in said SEQ ID NOs: or], and a complementary nucleotide sequence thereto.

16. (Amended) The isolated pathogenic *Leptospira* bacterium according to [any one of] Claim[s] 1 [to 14], wherein said bacterium further comprises a rRNA gene sequence

selected from the group consisting of: a nucleotide sequence which is at least 80% identical to [the nucleotide sequence 5'-TGTTGGA-3']SEQ ID NO:4, [or] a nucleotide sequence at least 90% identical to [the nucleotide sequence 5'-TTTGATA-3']SEQ ID NO:5, [or] a homologue, analogue or derivative thereof, and [or] a complementary nucleotide sequence thereto.

17. (Amended) The isolated pathogenic *Leptospira* bacterium according to Claim 16, wherein the rRNA gene sequence comprises a nucleotide sequence which is at least 85% identical to the [nucleotide sequence 5'-TGTTGGATCACAAAGATTTGATA]SEQ ID NO:7 or a homologue, analogue or derivative thereof or a complementary nucleotide sequence thereto.

18. (Amended) The isolated pathogenic *Leptospira* bacterium according to **[any one of]** Claim[s] 15 **[to 17]**, wherein the percentage identity is at least about 97%.

19. (Amended) The isolated pathogenic *Leptospira* bacterium according to **[any one of]** Claim[s] 1 **[to 18]**, having the characteristics of the microorganism deposited under AGAL Accession No. N95/69684 or which is serologically cross-reactive thereto.

21. (Amended) The isolated pathogenic *Leptospira* bacterium according to **[any one of]** Claim[s] 1 **[to 20]**, said method comprising the steps of:

- (i) collecting tissue from a human or other animal subject infected therewith;
- (ii) [homogenising]homogenizing said tissue in a suitable [homogenisation]homogenization medium for a time and under conditions sufficient to release said bacterium from said tissue whilst maintaining the integrity of said bacterium; and
- (iii) culturing the [homogenised]homogenized tissue in a suitable culture medium for a time and under conditions sufficient to allow said bacterium to grow.

23. (Amended) The method according to Claim[s] 21[-22], wherein the culture medium is supplemented with 8-azaguanine or 5-fluorouracil.

24. (Amended) The method according to **[any one of]** Claim[s] 21 **[to 23]**, wherein the culture medium is supplemented with at least one antibiotic.

26. (Amended) The method according to **[any one of]** Claim[s] 21 **[to 25]**, wherein the culture conditions comprise growth in the temperature range from about 13°C to about 37°C.

27. (Amended) The method according to **[any one of]** Claim[s] 21 **[to 26]**, wherein the other animal subject is a livestock animal or a companion animal.

30. (Amended) The method according to any [any one of] Claim[s] 21 [to 29], wherein the tissue is selected from the group consisting of: blood, serum, plasma, urine, cerebrospinal fluid, liver, lung [or] and tissue derived from the urogenital tract [selected from the list comprising bladder, kidney, uterus or fallopian tube or testes].

32. (Amended) An antibody molecule which is capable of binding to the isolated *Leptospira* bacterium [according to any one of Claims 1-20] of Claim 1 or an antigen derived from said bacterium.

33. (Amended) The method according to Claim 32, [further defined as] wherein said antibody molecule is a polyclonal antibody molecule.

34. (Amended) A method of diagnosing the presence of the pathogenic *Leptospira* bacterium [according to any one of Claims 1-20] of Claim 1 in a biological sample derived from a human or other animal subject, said method comprising contacting said biological sample or a nucleic acid molecule derived therefrom with one or more isolated probes or primers comprising a nucleotide sequence set forth in any one of SEQ ID NOs: 2-7 or a homologue, analogue or derivative thereof or a complementary sequence thereto for a time and under conditions sufficient for hybridisation to occur and then detecting said hybridisation using a detecting means.

38. (Amended) The method according to Claim 37, wherein the polymerase chain reaction employs at least one primer comprising a nucleotide sequence [set forth in] selected from the group consisting of: [SEQ ID NOs: 2 or SEQ ID NOs: 3 or ]SEQ ID NO:2, SEQ ID NO:3, and a derivative thereof.

39. (Amended) The method according to Claim 37, wherein the polymerase chain reactions employs two primers comprising the nucleotide sequences set forth in SEQ ID NOs: 2 and 3 or a derivative of any one of said nucleotide sequences.

40. (Amended) The method according to [any one of] Claim[s] 37[-39], comprising a nested PCR wherein:

- (i) the first amplified gene sequence obtained from a first round of amplification is contacted with one or more second nucleic acid primers of at least about 15 nucleotides in length derived from the nucleotide sequence set forth in SEQ ID NO: 1 or a complementary sequence thereto capable of [hybridising] hybridizing at a position in said first amplified gene sequence which is internal to

the position of the nucleic acid primer sequence(s) used to generate said first amplified gene sequence; and

(ii) copies of said first amplified gene sequence are amplified using PCR to produce a second amplified product comprising *Leptospira* serovar hurstbridge or serogroup Hurstbridge rRNA gene sequences.

41. (Amended) The method according to **[any one of]** Claim[s] 37[-40], comprising the further step of sequencing the amplified nucleic acid molecule product.

42. (Amended) A method of diagnosing the presence of the pathogenic *Leptospira* bacterium **[according to any one of Claims 1-20]** of Claim 1 in a biological sample derived from a human or other animal subject, said method comprising contacting said biological sample with an antibody molecule that binds to said bacterium or an antigen thereof for a time and under conditions sufficient for an antibody antigen complex to occur and then detecting said complex using a detecting means.

44. (Amended) The method according to Claim[s] 42 **[or 43]** comprising an immunoassay or serological assay.

45. (Amended) The method according to Claim 44, wherein the immunoassay or serological assay comprises MAT or ELISA.

46. (Amended) A method of diagnosing the presence of the pathogenic *Leptospira* bacterium **[according to any one of Claims 1-20]**of Claim 1 in a human or other animal subject, said method at least comprising the steps of culturing cells or tissue derived from said subject under selective culture conditions which are specific for said bacterium for a time and under conditions sufficient to allow said bacterium to grow.

49. (Amended) The method according to Claim 48, wherein the antibiotic is selected from the **[list comprising]**group consisting of: rifamycin, macrolide polyene and quinoline or a derivative compound thereof.

50. (Amended) The method according to **[any one of Claims 34-49]**Claim 34, wherein the other animal subject is a livestock animal or a companion animal.

51. (Amended) The method according to Claim 50, wherein the livestock animal or companion animal is selected from the **[list comprising]**group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

54. (Amended) The method according to **[any one of Claims 34-53]**Claim 34, wherein the biological sample comprises a sample selected from the group consisting of: a homogenate **[or]**, tissue **[or]**, cell extract **[or]**, whole cells **[or]**, tissues derived from serum, tissues derived from blood, tissues derived from urine, tissues derived from cerebrospinal fluid, tissues derived from liver, tissues derived from lung, tissues derived from bladder, tissues derived from kidney, tissues derived from uterus, tissues derived from fallopian tube **[or]**and tissues derived from testes.

55. (Amended) The method according to Claim 54, wherein the **[tissue is]** the biological sample comprises a sample selected from the group consisting of: a homogenate **[or]**, tissue **[or]**, cell extract **[or]**, whole cells **[or]**, tissues derived from serum, tissues derived from blood, tissues derived from urine **[or]**and tissues derived from kidney.

56. (Amended) A diagnostic kit for the detection of the pathogenic *Leptospira* bacterium **[according to any one of Claims 1-20]**of Claim 1 in a human or other animal subject or a biological sample derived therefrom, said kit at least comprising **[a first compartment which contains]** one or more immunogens derived from said pathogenic *Leptospira* bacterium and **[a second compartment which contains]** an antibody molecule that binds to said bacterium or an antigen thereof.

57. (Amended) A diagnostic kit for the detection of the pathogenic *Leptospira* bacterium **[according to any one of Claims 1-20]**of Claim 1 in a human or other animal subject or a biological sample derived therefrom, said kit at least comprising **[a first compartment which contains]** two noncomplementary nucleic acid primer molecules of at least about 15 nucleotides in length comprising a nucleotide sequence **[set forth in any one]**selected from the group consisting of: of SEQ ID NOs: 2-7 and **[a second compartment which contains]** a reaction buffer suitable for the performance of a nucleic acid hybridisation reaction or polymerase chain reaction.

58. (Amended) A composition which is capable of conferring protective immunity against the pathogenic *Leptospira* bacterium **[according to any one of Claims 1-20]**of Claim 1 in a human or animal subject, said composition comprising an attenuated form of said pathogenic *Leptospira* bacterium or one or more isolated or recombinant immunogens which are immunologically cross-reactive with a cellular component thereof and one or more pharmaceutically or veterinarily acceptable carriers, adjuvants and/or diluents.

60. (Amended) The composition according to Claim[s] 58 [or 59], wherein the pathogenic *Leptospira* bacterium is present at a concentration of at least about  $10^8$  organism per unit dose.

62. (Amended) A composition which is capable of conferring protective immunity against the pathogenic *Leptospira* bacterium [according to any one of Claims 1-20]of Claim 1 in a human or animal subject, said composition comprising serum derived from a human or other animal which [is infected with]contains said pathogenic *Leptospira* bacterium or a derivative product of said serum, and one or more pharmaceutically or veterinarily acceptable carriers, adjuvants and/or diluents, wherein said serum or derivative comprises antibodies which are capable of binding to the pathogenic *Leptospira* bacterium or to one or more immunogens thereof.

64. (Amended) A method of prophylactic or therapeutic treatment of infection of a human or animal subject by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or serologically cross-reactive derivative thereof, said method comprising administration of the composition according to [any one of Claims 58-63]Claim 58 to said human or animal subject for a time and under conditions sufficient to induce an immune response in said subject.

66. (Amended) A method of prophylactic or therapeutic treatment of leptospirosis in a human or animal subject comprising administration of the composition according to [any one of Claims 58-63]Claim 58 to said subject for a time and under conditions sufficient for said subject to resist a subsequent challenge by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or a serologically cross-reactive derivative thereof.

67. (Amended) A method of prophylactic or therapeutic treatment of reproductive disease in a human or animal subject comprising administration of the composition [any one of Claims 58-63]Claim 58 to said subject for a time and under conditions sufficient for said subject to resist a challenge by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or a serologically cross-reaction derivative thereof.

68. (Amended) The method according to Claim 67, wherein the reproductive disease is associated with any symptom selected from the group consisting of: seasonal infertility, reduced farrowing, [foetal] fetal death in utero [or], spontaneous abortion in the

infected subject [or with], and increased weaning-to-mating period in the offspring of the infected subject.

69. (Amended) The method [according to any one of Claims 64-68] Claim 64, wherein the composition is administered by injection.

70. (Amended) The method according to [any one of Claims 64-69] Claim 64, wherein the subject being treated is a human.

71. (Amended) The method according to [any one of Claims 64-69] Claim 64, wherein the subject being treated is a livestock animal or a companion animal.

72. (Amended) The method according to Claim 71, wherein the livestock animal or companion animal is selected from the [list comprising] group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

**Please add the following claims:**

75. The isolated pathogenic *Leptospira* bacterium according to Claim 5 wherein said livestock and companion animals are selected from the group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

76. The method according to any Claim 30, wherein the tissue derived from the urogenital tract is selected from the group consisting of: bladder, kidney, uterus, fallopian tube and testes.

77. The method according to Claim 42, wherein the other animal subject is a livestock animal or a companion animal.

78. The method according to Claim 77, wherein the livestock animal or companion animal is selected from the group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

79. The method according to Claim 78, wherein the livestock animal is a pig.

80. The method according to Claim 78, wherein the livestock animal is a bovine animal.

81. The method according to Claim 42, wherein the biological sample comprises a sample selected from the group consisting of: homogenate, tissue, cell extract, whole cells, tissues derived from serum, tissues derived from blood, tissues derived from urine, tissues derived from cerebrospinal fluid, tissues derived from liver, tissues derived from lung, tissues

derived from bladder, tissues derived from kidney, tissues derived from uterus, tissues derived from fallopian tube, and tissues derived from testes.

82. The method according to Claim 81, wherein the biological sample comprises a sample selected from the group consisting of: homogenate, tissue, cell extract, whole cells, tissues derived from serum, tissues derived from blood, tissues derived from urine, and tissues derived from kidney.

83. The method according to Claim 46, wherein the other animal subject is a livestock animal or a companion animal.

84. The method according to Claim 83, wherein the livestock animal or companion animal is selected from the group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

85. The method according to Claim 84, wherein the livestock animal is a pig.

86. The method according to Claim 84, wherein the livestock animal is a bovine animal.

87. The method according to Claim 46, wherein the biological sample comprises a sample selected from the group consisting of: homogenate, tissue, cell extract, whole cells, tissues derived from serum, tissues derived from blood, tissues derived from urine, tissues derived from cerebrospinal fluid, tissues derived from liver, tissues derived from lung, tissues derived from bladder, tissues derived from kidney, tissues derived from uterus, tissues derived from fallopian tube, and tissues derived from testes.

88. The method according to Claim 87, wherein the biological sample comprises a sample selected from the group consisting of: homogenate, tissue, cell extract, whole cells, tissues derived from serum, tissues derived from blood, tissues derived from urine, and tissues derived from kidney.

89. A method of prophylactic or therapeutic treatment of infection of a human or animal subject by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or serologically cross-reactive derivative thereof, said method comprising administration of the composition according to Claim 62 to said human or animal subject for a time and under conditions sufficient to induce an immune response in said subject.

90. The method according to Claim 89, wherein the immune response is a humoral immune response.

91. A method of prophylactic or therapeutic treatment of leptospirosis in a human or animal subject comprising administration of the composition according to Claim 62 to said subject for a time and under conditions sufficient for said subject to resist a subsequent challenge by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or a serologically cross-reactive derivative thereof.

92. A method of prophylactic or therapeutic treatment of reproductive disease in a human or animal subject comprising administration of the composition according to Claim 62 to said subject for a time and under conditions sufficient for said subject to resist a challenge by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or a serologically cross-reaction derivative thereof.

93. The method according to Claim 90, wherein the reproductive disease is associated with seasonal infertility, reduced farrowing, foetal death *in utero* or spontaneous abortion in the infected subject or with increased weaning-to-mating period in the offspring of the infected subject.

94. The method according to Claim 68, wherein the composition is administered by injection.

95. The method according to Claim 68, wherein the subject being treated is a human.

96. The method according to Claim 68, wherein the subject being treated is a livestock animal or a companion animal.

97. The method according to Claim 96, wherein the livestock animal or companion animal is selected from the group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

98. The method according to Claim 97, wherein the livestock animal is a pig.

99. The method according to Claim 97, wherein the livestock animal or companion animal is a bovine animal.

100. The method according to Claim 67, wherein the composition is administered by injection.

101. The method according to Claim 67, wherein the subject being treated is a human.

102. The method according to Claim 67, wherein the subject being treated is a livestock animal or a companion animal.

91. A method of prophylactic or therapeutic treatment of leptospirosis in a human or animal subject comprising administration of the composition according to Claim 62 to said subject for a time and under conditions sufficient for said subject to resist a subsequent challenge by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or a serologically cross-reactive derivative thereof.

92. A method of prophylactic or therapeutic treatment of reproductive disease in a human or animal subject comprising administration of the composition according to Claim 62 to said subject for a time and under conditions sufficient for said subject to resist a challenge by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or a serologically cross-reaction derivative thereof.

93. The method according to Claim 90, wherein the reproductive disease is associated with seasonal infertility, reduced farrowing, foetal death *in utero* or spontaneous abortion in the infected subject or with increased weaning-to-mating period in the offspring of the infected subject.

94. The method according to Claim 68, wherein the composition is administered by injection.

95. The method according to Claim 68, wherein the subject being treated is a human.

96. The method according to Claim 68, wherein the subject being treated is a livestock animal or a companion animal.

97. The method according to Claim 96, wherein the livestock animal or companion animal is selected from the group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

98. The method according to Claim 97, wherein the livestock animal is a pig.

99. The method according to Claim 97, wherein the livestock animal or companion animal is a bovine animal.

100. The method according to Claim 67, wherein the composition is administered by injection.

101. The method according to Claim 67, wherein the subject being treated is a human.

102. The method according to Claim 67, wherein the subject being treated is a livestock animal or a companion animal.

103. The method according to Claim 102, wherein the livestock animal or companion animal is selected from the group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

104. The method according to Claim 103, wherein the livestock animal is a pig.

105. The method according to Claim 103, wherein the livestock animal or companion animal is a bovine animal.

106. The method according to Claim 87, wherein the composition is administered by injection.

107. The method according to Claim 87, wherein the subject being treated is a human.

108. The method according to Claim 87, wherein the subject being treated is a livestock animal or a companion animal.

109. The method according to Claim 108, wherein the livestock animal or companion animal is selected from the group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

110. The method according to Claim 109, wherein the livestock animal is a pig.

111. The method according to Claim 109, wherein the livestock animal or companion animal is a bovine animal.

112. The method according to Claim 89, wherein the composition is administered by injection.

113. The method according to Claim 89, wherein the subject being treated is a human.

114. The method according to Claim 89, wherein the subject being treated is a livestock animal or a companion animal.

115. The method according to Claim 114, wherein the livestock animal or companion animal is selected from the group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

116. The method according to Claim 115, wherein the livestock animal is a pig.

117. The method according to Claim 115, wherein the livestock animal or companion animal is a bovine animal.

118. The method according to Claim 91, wherein the composition is administered by injection.

119. The method according to Claim 91, wherein the subject being treated is a human.

120. The method according to Claim 91, wherein the subject being treated is a livestock animal or a companion animal.

121. The method according to Claim 118, wherein the livestock animal or companion animal is selected from the group consisting of: pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

122. The method according to Claim 121, wherein the livestock animal is a pig.

123. The method according to Claim 121, wherein the livestock animal or companion animal is a bovine animal.

**IN THE ABSTRACT:**

Please insert the attached page 92 as the abstract for the application.

**REMARKS**

The claims have been amended to conform with the rules of practice before the Patent and Trademark Office. The specification has been amended to recite the International Application and priority application. The word "CLAIMS" has been deleted and substituted by "WHAT IS CLAIMED IS". Claim 43 has been deleted, claims 75-123 have been added. As a result of this preliminary amendment, Claims 1-42 and 44-123 are presented for examination. No new matter is being added herewith.

**Conclusion**

Should there be any questions concerning this application, the Examiner is invited to contact the undersigned attorney at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 7 Sept. 1999

By:

Daniel E. Altman

Daniel E. Altman

Registration No. 34,115

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(949) 760-0404

3/PRTS

514 Rec'd PCT/PTO 07 SEP 1999

WO 98/40099

PCT/AU98/00145

- I -

LEPTOSPIRA PATHOGENS

The present invention relates generally to novel isolated species of pathogenic bacteria and to immunoreactive molecules which are derived therefrom and their use in compositions of matter such as vaccine preparations. The compositions of the present invention are useful in protecting host organisms against bacterial infections. More particularly, the present invention is directed to an isolated serogroup, serovar or species of bacteria belonging to the genus *Leptospira*. Even more particularly, the present invention is directed to a new isolated species of *Leptospira* designated as "*L. fainei*" or a new isolated *L. fainei* serovar designated as "hurstbridge" and to bacteria belonging to the same serogroup as serovar hurstbridge or *L. fainei*, designated as "serogroup Hurstbridge" and to diagnostic assays therefor. The present invention is further directed to methods of detection, identification and quantification of *Leptospira*, such as those *Leptospira* belonging to serogroup Hurstbridge and more particularly to methods of detection of *L. fainei* and even more particularly to methods of detection of serovar hurstbridge. The present invention further provides vaccine compositions which provide for the passive and active vaccination of human or animal hosts against *Leptospira*, such as those *Leptospira* belonging to serogroup Hurstbridge and more particularly to vaccine compositions against *L. fainei* serovar hurstbridge.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

As used herein, the term "derived from" shall be taken to indicate that a particular integer or group of integers has originated from the species specified, but has not necessarily been obtained directly from the specified source.

Bibliographic details of the publications referred to by author in this specification are

WO 98/40099

PCT/AU98/00145

- 2 -

collected at the end of the description. Sequence identity numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined after the bibliography.

- 5 Bacteria of the genus *Leptospira* are either pathogenic or saprophytic spirochaetes comprising several known species (Pathogenic: *L.interrogans*, *L.inadai*, *L.borgpetersenii*, *L. santarosai*, *L. kirschneri*, *L. weilii* or *L. noguchii* ; Saprophytic: *L. biflexa*, *L. meyeri* or *L. wolbachii*), each of which comprises a large number of serovars. Saprophytic serovars of *Leptospira* are omnipresent in fresh surface waters and occasionally found in sea water.
- 10 Pathogenic *Leptospira* serovars occur naturally in a large variety of livestock animals, companion animals, wild animals and humans. The host range of *Leptospira* serovars is generally quite broad, however the bacterium may produce differing symptoms in each host organism which it has infected.
- 15 In a primary (maintenance) host in which a pathogenic *Leptospira* serovar is maintained, reproductive disease is typical. Alternatively, infection may be asymptomatic. Pathogenic *Leptospira* serovars may also cause acute, febrile, systemic disease in mammals. Acute febrile disease is also characteristic of many human infections.
- 20 In livestock animals such as pigs and possibly horses and dogs or other species, the pathogen *L.interrogans* serovar bratislava causes reproductive disease leading to infertility, abortions or stillbirth and has been cited as a possible causative agent of seasonal infertility ( Chappel *et al.*, 1993a,b; Ellis *et al.*, 1983; Ellis *et al.*, 1985; Ellis *et al.*, 1986a,b; Frantz *et al.*, 1988). Infection with *L.interrogans* serovar bratislava is endemic in European and
- 25 North American swine herds. In Australian swine herds, the pathogenic serovars *L.interrogans* serovar pomona and *L. borgpetersenii* serovar tarassovi have long been recognised ( Chappel *et al.*, 1987a,b; Chappel *et al.*, 1990; Davos, 1977). however many Australian herds have also tested positive for the presence of *L.interrogans* serovar bratislava using the microscopic agglutination test, hereinafter referred to as "MAT"
- 30 (Chappel *et al.*, 1992; Chappel *et al.*, 1993a,b). *Leptospira interrogans* serovar bratislava

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:46PM

WO 98/40099

PCT/AU98/00145

- 3 -

is notoriously recalcitrant to standard isolation techniques, using samples from the infected host organism as starting material. This factor has to date prevented the preparation in Australia of vaccines which protect animals specifically against infection by serovar bratislava.

5

In work leading up to the present invention, the inventors sought to isolate *Leptospira* serogroups and serovars, in particular *L.interrogans* serovar bratislava from swine herds with MAT titres to serovar bratislava and with immunochemical evidence of leptospiral infection. Surprisingly, a novel leptospire was isolated which does not cross-react in MATs with other pathogenic serovars including serovars bratislava, pomona and tarassovi. This new leptospire forms an antigenically-distinct serogroup and serovar, based upon microscopic agglutination assay (MAT) results and a genetically-distinct species, based upon nucleic acid hybridisation data. The new *Leptospira* and recombinant nucleic acid, polypeptides or immunoreactive molecules which are derived therefrom, and derivatives, homologues or analogues thereof, provide the means to develop a range of diagnostic and therapeutic agents for *Leptospira* infection which were hitherto not available.

Accordingly, one aspect of the present invention provides an isolated pathogenic *Leptospira* bacterium which belongs to serogroup Hurstbridge or serovar hurstbridge or the species *L. fainei* or derivative bacterium thereof.

The terms "serogroup" and "serovar" relate to a classification of *Leptospira* which is based upon serological typing data, in particular data obtained using agglutination assays such as the microscopic agglutination test (MAT).

25

The term "serovar" means one or more *Leptospira* strains which are antigenically-identical. Quantitatively, serovars are differentiated from one another by the cross-agglutination absorption technique as outlined by Faine (1994).

WO 98/40099

PCT/AU98/00145

- 4 -

In the present context, the term "serovar hurstbridge" shall be taken to include any leptospire which is cross-reactive according to the cross-agglutination absorption criteria (Faine, 1994) with the *Leptospira fainei* strain WKID deposited under AGAL Accession No. N95/69684 or the *L. fainei* strain BUT6. The term "serovar hurstbridge" is not to be  
5 limited in any way to those bacteria belonging to serogroup Hurstbridge as defined herein.

The term "serogroup" refers to a group of *Leptospira* whose members cross-agglutinate with shared group antigens and do not cross-agglutinate with the members of other groups and, as a consequence, the members of a serogroup have more or less close antigenic  
10 relations with one another by simple cross-agglutination.

Accordingly, the term "serogroup Hurstbridge" refers to a serological group of *Leptospira* whose members cross-agglutinate with shared group antigens of the *Leptospira fainei* strain WKID deposited under AGAL Accession No. N95/69684 or the *L. fainei* strain  
15 BUT6, however do not cross-agglutinate in a simple cross-agglutination test with the members of other groups known to those skilled in the art at the date of the present invention. The term "serogroup Hurstbridge" is not to be limited in any way to those bacteria belonging to serovar hurstbridge as hereinbefore defined.

20 The classification of *Leptospira* into different species will be known to those skilled in the art to refer to one leptospire whose total genomic DNA is less than 40% homologous to the genomic DNA of another leptospire. Accordingly, as used herein, the species definition "*Leptospira fainei*" or "*L. fainei*" shall be taken to refer to any leptospire bacterium which comprises genomic DNA which is at least 40% homologous to the genomic DNA derived  
25 from the *Leptospira* deposited under AGAL Accession No. N95/69684 or the *Leptospira* strain BUT6, as determined using standard genomic DNA hybridisation and analysis

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 5 -

techniques.

Those skilled in the art will be aware that serovar and serogroup antigens are a mosaic on the cell surface and, as a consequence there will be no strict delineation between bacteria  
5 belonging to serovar hurstbridge and/or serogroup Hurstbridge. Moreover, leptospires which belong to different species may be classified into the same serovar or serogroup because they are indistinguishable by antigenic determination.

The present invention clearly extends to any bacterium belonging to serovar hurstbridge  
10 or serogroup Hurstbridge or *Leptospira fainei*.

In connection with this invention, an exemplary *Leptospira fainei* bacterium of serogroup Hurstbridge or serovar hurstbridge has been deposited as depositor's reference WKID (VIAS), pursuant to and in satisfaction of, the Budapest Treaty on the International  
15 Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure, with the Australian Government Analytical Laboratories (AGAL), 1 Suakin Street, Pymble, New South Wales 2073, Australia (Postal Address: PO Box 385 Pymble NSW 2073 Australia) on 15 November, 1995 and accorded AGAL Accession Number N95/69684.

20 The *Leptospira* strains WKID and BUT6 were originally isolated from different herds of pigs in New South Wales, Australia and Victoria, Australia as described in the Examples (see, for example Table 3). Both of these isolates belong to the species now known as *Leptospira fainei*, based upon DNA hybridisation analysis, as well as belonging to the serogroup Hurstbridge and serovar hurstbridge, based upon serological criteria using MAT.

25

A "derivative" of the leptospiral bacterium of the invention is a bacterium which has been developed by mutation, recombination, conjugation or transformation of leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei* as hereinbefore defined. Preferably, a derivative of serogroup Hurstbridge or serovar hurstbridge or *L. fainei* is serologically  
30 cross-reactive or immunologically cross-reactive with serogroup Hurstbridge or serovar

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 6 -

hurstbridge as defined herein or genetically-related to *L. fainei* as hereinbefore defined, in particular the leptospire assigned AGAL Accession Number N95/69684 or *Leptospira* strain BUT 6. It will be known to a person skilled in the art how to produce such derivatives.

5

Accordingly, this aspect of the present invention relates to isolated pathogenic *Leptospira* bacteria which are antigenically cross-reactive in MAT with one or more antigenic determinants of the *Leptospira* deposited under AGAL Accession No. N95/69684 or the *Leptospira* strain BUT6 exemplified herein and/or which comprise genomic DNA which is at least 40% homologous to the genomic DNA derived from the *Leptospira* deposited under AGAL Accession No. N95/69684 or the *Leptospira* strain BUT6 or a derivative bacterium thereof.

In a particularly preferred embodiment of the invention, the bacterium belonging to *L. fainei* or serovar hurstbridge or serogroup Hurstbridge grows at temperatures from about 13°C to about 37°C, preferably at 13°C to 37°C and more preferably at temperatures of about 13°C. Additionally, it is particularly preferred that the subject *Leptospira* grows in the presence of 8-azaguanine or 5-fluorouracil, more preferably at least 100µg/ml 8-azaguanine, even more preferably at least 150µg/ml 8-azaguanine, still even more preferably at least 200µg/ml 8-azaguanine and even still more preferably at least 250µg/ml or up to and including a concentration of 500µg/ml 8-azaguanine.

In a more preferred embodiment, said bacterium is further capable of infecting a human or a livestock or companion animal, in particular a livestock or companion animal selected from the list comprising pigs, bovine, sheep, goats, horses, deer, alpacas, dogs or cats, amongst others.

In an even more preferred embodiment, said pathogenic *Leptospira* bacterium is capable of infecting said human or animal and inducing reproductive disease therein.

30

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 7 -

The term "reproductive disease" as used herein shall be taken to refer to any abnormality of the reproductive system of a human or other animal, in particular pigs or bovines which reduces the fecundity of said human or animal, for example an abnormality characterised by infertility of said human or animal including seasonal infertility or abnormal development of a foetus in said human or animal or spontaneous abortion of a foetus in said human or animal or failure to conceive by said human or animal. In the context of the present invention, the term "reproductive disease" shall also be taken to include reduced or slowed development, such as an increase in the weaning-to-mating period in animals which are infected during gestation or before becoming pregnant. Such reproductive disease is caused by infection of a human or animal with a pathogenic bacterium of the genus *Leptospira*, in particular leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or a derivative bacterium thereof.

In an alternative embodiment, the present invention provides an isolated *Leptospira* bacterium or derivative bacterium thereof which contains genetic sequences from nucleotide of the 16S ribosomal RNA (rRNA) gene which are at least 85% identical to the rRNA genetic sequences of *Leptospira inadai* serovar lyme and less than 80% identical to the rRNA genetic sequences of *Leptospira biflexa* serovar patoc, wherein said pathogenic bacterium is capable of growing at temperatures from about 13°C to about 37°C and/or in the presence of at least 100µg/ml 8-azaguanine, preferably at least 150µg/ml 8-azaguanine, more preferably at least 200µg/ml 8-azaguanine and even more preferably at least 250µg/ml, or up to and including a concentration of 500µg/ml 8-azaguanine.

In a preferred embodiment, the *Leptospira* bacterium or derivative serovar of the present invention is further characterised as a pathogenic bacterium.

More preferably, the pathogenic bacterium of the invention is further capable of infecting a livestock human or animal, in particular a human or livestock animal selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpacas or a companion animal such as a dog or cat, amongst others.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 8 -

According to this embodiment of the invention, wherein a pathogenic *Leptospira* bacterium infects said livestock animal, it is most preferred that said bacterium induces reproductive disease therein.

- 5 In another alternative embodiment of the present invention, there is provided an isolated *Leptospira* bacterium or derivative thereof which contains genetic sequences which are at least 80% identical to the nucleotide sequence set forth in any one of SEQ ID NOs:1-2 or 4-7 or a complement, or a derivative, homologue or analogue thereof.
- 10 It is preferred that the percentage identity to the nucleotide sequence set forth in any one of SEQ ID NOs:1-2 or 4-7 is at least 85%. According to this embodiment of the invention, it is more preferred that the genetic material of said pathogenic *Leptospira* bacterium or derivative bacterium thereof be at least 90% identical to any one of SEQ ID NOs:1-2 or 6-7, even more preferably at least 97% identical and still more preferably at least 99%
- 15 identical including 100% identical.

- For the purposes of nomenclature, the nucleotide sequence set forth in SEQ ID NO:1 relates to the nucleotide sequence of the rRNA gene of an isolate of serovar hurstbridge or serogroup Hurstbridge or *L. fainei*. The nucleotide sequences set forth in SEQ ID NOs:2-7
- 20 relate to primer sequences specific for the rRNA gene of serovar hurstbridge or serogroup Hurstbridge or *L. fainei* which the inventors have shown are particularly useful for the diagnostic detection of the pathogenic *Leptospira* bacterium of the species or serogroup Hurstbridge. More particularly, the nucleotide sequences set forth in SEQ ID NOs:2-3 are useful as a primer pair for the diagnostic detection of the pathogenic *Leptospira* bacterium
- 25 of the species or serogroup Hurstbridge using the polymerase chain reaction.

- In a further alternative embodiment, the present invention provides an isolated pathogenic *Leptospira* bacterium or derivative bacterium thereof which contains genetic material capable of hybridising under high stringency conditions to the nucleotide sequence set forth
- 30 in any one of SEQ ID NOs:1-2 or 4-7 or its complementary nucleotide sequence, or a

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 9 -

derivative, homologue or analogue thereof.

Preferably, said genetic material is selected from the list comprising RNA or DNA.

- 5 In a further alternative embodiment, the present invention provides an isolated *Leptospira* bacterium or derivative bacterium thereof which contains a rRNA gene which comprises a nucleotide sequence which is at least 80% identical to the nucleotide sequence 5'-TGTTGGA-3' or at least 90% identical to the nucleotide sequence 5'-TTTGATA-3' or at least 90% identical to the nucleotide sequence 5'-TGTTGGA(N), TTTGATA-3' or a  
10 complement, or a derivative, homologue or analogue thereof, wherein N is any nucleotide residue.

- More preferably, the isolated *Leptospira* bacterium of the present invention or a derivative bacterium thereof contains a rRNA gene which comprises a nucleotide sequence which is  
15 at least 85% identical to the nucleotide sequence 5'-TGTTGGATCACAAGATTTGATA-3' or a complement, or a derivative, homologue or analogue thereof.

- According to this embodiment, the inventors have discovered a region of the rRNA gene of a leptospire which is unique to the species *L. fainei* or serogroup Hurstbridge or serovar  
20 hurstbridge belongs and is particularly suited for diagnostic applications. The present invention clearly extends to isolated nucleotide sequences and oligonucleotides which comprise said nucleotide sequences.

- It is preferred that said pathogenic *Leptospira* bacterium is further capable of growing at  
25 temperatures from about 13°C to about 37°C and/or in the presence of at least 100µg/ml 8-azaguanine, preferably at least 150µg/ml 8-azaguanine, more preferably at least 200µg/ml 8-azaguanine and even more preferably at least 250µg/ml, or up to and including a concentration of 500µg/ml 8-azaguanine.

- 30 More preferably, the present invention provides an isolated pathogenic *Leptospira*

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 10 -

bacterium or derivative bacterium thereof which contains RNA or DNA capable of hybridising under high stringency conditions to the nucleotide sequence set forth in any one of SEQ ID NOs:1-2 or 4-7 or a complementary nucleotide sequence thereto or a derivative, homologue or analogue thereof, wherein said bacterium is further capable of growing at  
5 temperatures from about 13°C to about 37°C and/or in the presence of at least 100µg/ml 8-azaguanine, preferably at least 150µg/ml 8-azaguanine, more preferably at least 200µg/ml 8-azaguanine and even more preferably at least 250µg/ml, or up to and including a concentration of 500µg/ml 8-azaguanine.

- 10 For the purposes of defining the level of stringency, a high stringency is defined herein as being a Southern hybridisation and/or a wash thereafter carried out in 0.1xSSC buffer, 0.1% (w/v) SDS at 65°C. In Southern hybridisations, the stringency is generally increased by reducing the concentration of SSC buffer, and/or increasing the concentration of SDS and/or increasing the temperature of the hybridisation and/or wash. Conditions for Southern  
15 hybridisations and washes are well understood by one normally skilled in the art. For the purposes of clarification, (to parameters affecting hybridisation between nucleic acid molecules), reference is found in pages 2.10.8 to 2.10.16. of Ausubel *et al.* (1987), which is herein incorporated by reference.
- 20 Alternatively, a high stringency is also defined according to the conditions which are appropriate for the annealing of nucleic acid primers in a polymerase chain reaction (PCR) as exemplified herein.

In a particularly preferred embodiment of the present invention, there is provided an  
25 isolated bacterium or serogroup which:

1. Is a pathogenic species belonging to the genus *Leptospira*;
2. Grows at temperatures in the range from about 13°C to about 37°C;
3. Grows in media containing at least 225µg/ml 8-azaguanine;
4. Is capable of infecting a human or a livestock or companion animal, in  
30 particular a livestock or companion animal selected from the list comprising pigs,

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 11 -

bovines, sheep, goats, horses, deer, alpacas, dogs or cats, amongst others;

5. Is capable of inducing reproductive disease as hereinbefore defined in at least one of said infected animal: and

6. Contains a genetic sequence which comprises a sequence of nucleotides or is complementary to a genetic sequence which comprises a sequence of nucleotides which is at least 80% identical to the nucleotide sequence set forth in any one of SEQ ID NOs:1-2 or 4-7 or a complementary nucleotide sequence thereto or a derivative, homologue or analogue thereof.

10 In a most particularly preferred embodiment, the present invention provides an isolated pathogenic *Leptospira* bacterium belonging to serogroup Hurstbridge or serovar hurstbridge or *L. fainei* which possesses the characteristics or attributes of the microorganism deposited with AGAL under AGAL Accession Number N95/69684 or is within the same serogroup (as defined by Faine, 1994) as the microorganism N95/69684 or is in the same species as the microorganism N95/69684 or is immunologically cross-reactive with the microorganism N95/69684 in a microscopic agglutination test (MAT).

Even more preferably, bacteria belonging to serovar hurstbridge or serogroup Hurstbridge or *L. fainei* as defined herein are pathogens of humans and/or livestock or companion animals. in particular livestock or companion animals selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpacas, dogs or cats, amongst others.

A further embodiment of the present invention provides an isolated serovar of leptospiral serovar hurstbridge as hereinbefore defined or a derivative bacterium thereof. Preferably, said serovar of a leptospiral serovar hurstbridge is genetically-cross-reactive or immunologically-cross-reactive with the strain deposited with AGAL under Accession No. N95/69684 on 15 November, 1995.

More preferably, said serovar is identical to the strain deposited with AGAL under Accession No. N95/69684 on 15 November, 1995.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 12 -

According to this embodiment of the invention, said isolated serovar may be determined to be immunologically-cross-reactive or genetically-cross-reactive or genetically-cross-hybridising with the serovar of the leptospire deposited under AGAL Accession No, N95/69684 by any means known to those skilled in the relevant art, including, but not  
5 limited to, serological, immunological, or molecular-biological means. Serological means include MAT titre estimations (Cole et al., 1973; Chappel, 1993a). Immunological means include ELISA, Western blot immunoelectrophoresis, immunodiffusion techniques, rocket gel electrophoresis, radio-immunoassay techniques, amongst others. Molecular-biological means include nucleic acid hybridisation, nucleic acid sequencing techniques, polymerase  
10 chain reaction techniques and variations thereto, amongst others. Those skilled in the relevant art will be aware of variations and optimisations which may be applied to these procedures, in typing the leptospire of the invention.

The invention described according to this aspect extends to said isolated bacterium when  
15 provided as a culture in liquid or solid form, such as but not limited to a glycerol stock, stab, slope, plate or in a freeze-dried or otherwise-dried form, for example on a membraneous filter or paper disc.

A second aspect of the present invention is directed to a method of isolation of the  
20 pathogenic *Leptospira* serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or an immunologically-cross-reactive or a genetically-cross-reactive serovar or a derivative bacterium thereof comprising the steps of:

- 25 1. Collection of human or animal tissue from a host organism which is infected with said pathogen;
2. Homogenisation of said tissue in homogenisation medium suitable for maintaining the integrity of said pathogenic bacterium; and
3. Culture of said tissue containing said *Leptospira* bacterium in a culture medium for a time sufficient to allow bacteria to grow to the required density.

30

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 13 -

The culture medium may be any medium appropriate for the purpose of culturing a *leptospira* bacterium, which are generally known to those skilled in the art, for example EMJH medium described by Chappel (1993b).

- 5 According to this aspect of the present invention, a person skilled in the art would be aware that said culture of *Leptospira* may require sub-culturing at certain intervals, in order to maintain the viability of the culture. Such sub-culturing serves to replace nutrients in the media which are essential to viability and/or growth of the bacterium. If sufficient cycles of sub-culturing are carried out, this will eventually produce a bacterial culture which is
- 10 essentially free of contaminating tissue derived from the host organism.

- Preferably, the human or animal tissue from which said pathogen is obtained is blood or tissue of the urogenital tract selected from the list comprising bladder, kidney, uterus or fallopian tube, testes or ovaries or, alternatively, from liver or lung tissue, or from body
- 15 fluids or exudates such as urine or cerebrospinal fluid, amongst other sources. More preferably, said tissue originates from a preferred host of the pathogenic leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, in particular a human or a livestock or companion animal selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpacas, dogs or cats, amongst others.

- 20 It will be understood by those skilled in the art that there are a range of suitable homogenisation media which may be used, the only requirement being that the particular homogenisation medium used maintains the bacterium in a viable state such that sufficient viable cells exist in the homogenate to establish a viable culture.

- 25 The present invention extends to the use of any suitable homogenisation medium in the isolation of the subject leptospire including, for example, media containing phosphate-buffered albumin.

- 30 Preferably, the culture medium contains in addition to 8-azaguanine, 5-fluorouracil and at

WO 98/40099

PCT/AU98/00145

- 14 -

least one antibiotic selected from the list comprising a rifamycin, macrolide polyene or quinoline antibiotic, amongst others.

Rifamycin antibiotics are high substituted macrocyclic compounds which are active against Gram-positive bacteria and certain Gram-negative bacteria but to which spirochaete bacteria including *Leptospira* bacteria are resistant. Rifamycins specifically inhibit eubacterial DNA-dependent RNA polymerase, binding to the  $\beta$ -subunit and inhibiting transcription.

The macrolide polyenes are characterised by a substituted or unsubstituted lactone ring containing a rigid, lipophilic region of unsubstituted *trans*-conjugated double bonds and a flexible, hydrophilic hydroxylated region. Macrolide polyenes interact with sterols in the cytoplasmic membrane, causing leakage of ions and small molecules. Macrolide antibiotics are not effective against bacteria which do not contain sterols in their membranes. Macrolide antibiotics are microbistatic at low concentrations or microbicidal at higher concentrations against yeast and other fungi and against protozoa which contain sterols in their membranes. Preferred macrolide polyenes are selected from the list comprising amphotericin, aureofungin, candicidin B, etruscomycin, filipin, hamycin, hystatin, perimycin, pimaricin and trichomycin amongst others.

Quinoline antibiotics contain a substituted 4-quinoline ring and are primarily active against Gram-negative bacteria. Preferred quinoline antibiotics include but are not limited to antibiotics selected from the list comprising naladixic acid, cinoxacin, oxolinic acid, pipemidic acid, ciprofloxacin, enoxacin, norfloxacin, ofloxacin or perfloxacin, amongst others.

The list of antibiotics provided for the isolation of a *Leptospira* bacterium according to the present invention is not exhaustive and the person skilled in the art will appreciate that alternative or additional antibiotics may be used. The person skilled in the art will also be aware that the tissue from which the pathogenic leptospire is to be isolated may contain

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:45PM

WO 98/40099

PCT/AU98/00145

- 15 -

several contaminating microorganisms in addition to said *Leptospira* bacterium and the particular combination of antibiotics selected for use will vary depending upon the nature of the contaminating microorganisms present. The present invention clearly contemplates the use of additional antibiotics in the culture media used for the isolation of said  
5 pathogenic *Leptospira* bacterium.

In a particularly preferred embodiment, the present invention provides a method of isolation of a pathogenic *Leptospira* bacterium as hereinbefore described wherein said bacterium is a serovar which has been deposited with AGAL on 15 November, 1995 and assigned  
10 AGAL Accession Number N95/69684.

In a particularly preferred embodiment, said method is useful for the isolation of the pathogenic *Leptospira* bacterium deposited with AGAL on 15 November, 1995 and assigned AGAL Accession Number N95/69684.  
15

A third aspect of the present invention provides agents and chemical compositions for use in the isolation of the pathogenic leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or a derivative bacterium thereof, essentially according to the methods described herein.  
20

In a preferred embodiment, the agent or chemical composition is a culture medium for the selective growth of the leptospire of the invention.

According to this aspect of the present invention, the agent or chemical composition may  
25 be in powdered, liquid, tablet, pellet, capsule or other form.

The present invention extends to an agent or chemical composition as described herein, wherein said agent or chemical composition is used for, or intended to be used for the isolation, detection, purification, culture or storage of a pathogenic microorganism,  
30 preferably a pathogenic bacterium, more preferably a pathogenic *Leptospira* bacterium in

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

WO 98/40099

PCT/AU98/00145

- 16 -

particular the leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei* such as the strain deposited under AGAL Accession Number N95/69684 or a derivative bacterium thereof.

- 5 A fourth aspect of the present invention provide an isolated nucleic acid molecule comprising a sequence of nucleotides which corresponds to, or is complementary to a sequence of nucleotides which corresponds to the 16S rRNA gene or a derivative, homologue or analogue thereof of the pathogenic *Leptospira* bacterium of the present invention.

10

Reference herein to "genes" is to be taken in its broadest context and includes:

- (i) a classical genomic gene consisting of transcriptional and/or translational regulatory sequences and/or a coding region and/or non-translated sequences (i.e. introns, 5'- and 3'- untranslated sequences); or
- 15 (ii) mRNA or cDNA corresponding to the coding regions (i.e. exons) and 5'- and 3'-untranslated sequences of the gene.

The term "gene" is also used to describe synthetic or fusion molecules encoding all or part of a functional product. Preferred rRNA genes may be derived from a naturally-occurring

20 serovar, in particular the rRNA gene of serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, by standard recombinant techniques. Generally, a rRNA gene may be subjected to mutagenesis to produce single or multiple nucleotide substitutions, deletions and/or additions. Nucleotide insertional derivatives of a rRNA gene of the present invention include 5' and 3' terminal fusions as well as intra-sequence insertions of single or multiple

25 nucleotides. Insertional nucleotide sequence variants are those in which one or more nucleotide are introduced into a predetermined site in the nucleotide sequence although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterised by the removal of one or more nucleotides from the sequence. Substitutional nucleotide variants are those in which at least one nucleotide in

30 the sequence has been removed and a different nucleotide inserted in its place.

WO 98/40099

PCT/AU98/00145

- 17 -

Accordingly, the isolated nucleic acid molecule of the present invention may comprise genomic DNA, cDNA, RNA or a synthetic oligonucleotide molecule in single-stranded or double-stranded form. The present invention further extends to conformational isomers of such molecules.

5

Preferably, the isolated nucleic acid molecule comprises a nucleotide sequence which is at least 80% identical to the nucleotide sequence set forth in any one of SEQ ID NOs:1-2 or 4-7 or a complement, or a derivative, homologue or analogue thereof.

- 10 In an alternative embodiment, the isolated nucleic acid molecule at least comprises a nucleotide sequence which is at least 80% identical to the nucleotide sequence 5'-TGTTGGA-3' or at least 90% identical to the nucleotide sequence 5'-TTTGATA-3' or at least 90% identical to the nucleotide sequence 5'-TGTTGGA(N)<sub>8</sub>TTTGATA-3' or a complement, or a derivative, homologue or analogue thereof, wherein N is any nucleotide  
15 residue.

More preferably, the isolated nucleic acid molecule comprises a nucleotide sequence which is at least about 85% identical to the nucleotide sequence:

5'-TGTTGGATCACAAGATTTGATA-3'

- 20 or a complement, or a derivative, homologue or analogue thereof.

- Alternatively or in addition, the isolated nucleic acid molecule is capable of hybridising under high stringency conditions to any one of the nucleotide sequences described *supra* or to its complementary nucleotide sequence, or a derivative, homologue or analogue  
25 thereof.

- For the present purpose, homologues of a nucleotide sequence shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as or at least 80% identical to a nucleic acid molecule of the present invention or its complementary nucleotide  
30 sequence, notwithstanding the occurrence within said sequence, of one or more nucleotide

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

WO 98/40099

PCT/AU98/00145

- 18 -

substitutions, insertions, deletions, or rearrangements.

5 Analogues of a nucleotide sequence set forth herein shall be taken to refer to an isolated nucleic acid molecule which is substantially the same as a nucleic acid molecule of the present invention or its complementary nucleotide sequence, notwithstanding the occurrence of any non-nucleotide constituents not normally present in said isolated nucleic acid molecule, for example carbohydrates, radiochemicals including radionucleotides, reporter molecules such as, but not limited to DIG, alkaline phosphatase or horseradish peroxidase, amongst others.

10

Derivatives of a nucleotide sequence set forth herein shall be taken to refer to any isolated nucleic acid molecule which contains significant sequence similarity to said sequence or a part thereof. Generally, the nucleotide sequence of the present invention may be subjected to mutagenesis to produce single or multiple nucleotide substitutions, deletions and/or insertions. Nucleotide insertional derivatives of the nucleotide sequence of the present invention include 5' and 3' terminal fusions as well as intra-sequence insertions of single or multiple nucleotides or nucleotide analogues. Insertional nucleotide sequence variants are those in which one or more nucleotides or nucleotide analogues are introduced into a predetermined site in the nucleotide sequence of said sequence, although random insertion is also possible with suitable screening of the resulting product being performed. Deletional variants are characterised by the removal of one or more nucleotides from the nucleotide sequence. Substitutional nucleotide variants are those in which at least one nucleotide in the sequence has been removed and a different nucleotide or nucleotide analogue inserted in its place.

25

Preferred homologues, analogues and derivatives comprise at least about 5-15 nucleotides in length and more preferably at least about 15-30 nucleotides in length and are at least about 80% identical to the nucleotide sequences of the invention described herein. Alternatively, the homologues, analogue and derivatives described herein may further comprise a nucleotide sequence which is at least about 90% identical, more preferably at

30

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

66221" 92303E60

WO 98/40099

PCT/AU98/00145

- 19 -

least about 95% identical, even more preferably at least about 97% identical and still more preferably at least about 99% identical to any one of the nucleotide sequences of the invention described herein. Particularly preferred homologues, analogues and derivatives comprise at least about 15-18 nucleotides in length derived from any one of the nucleotide sequences of the invention described herein.

For the purposes of the present invention, it is preferred that the nucleic acid molecule of the invention is the 16S rRNA genetic sequence of the leptospire which has been deposited with AGAL under Accession Number N95/69684. It will be known to those skilled in the relevant art that derivative bacteria of the deposited leptospire or bacteria belonging to the same species will generally contain 16S rRNA genetic sequences which are more closely related to the 16S rRNA of serovar hurstbridge or serogroup Hurstbridge or *L. fainei* than are the 16S rRNA genetic sequences obtained from more distantly-related, or unrelated *Leptospira*. As a consequence, the genetic sequence of the present invention is at least useful in determining whether or not a pathogenic *Leptospira* bacterium is closely related to serovar hurstbridge or serogroup Hurstbridge or *L. fainei*. Said genetic sequence is also useful in the isolation of genetic sequences from serovars of *Leptospira* which are closely-related to serovar hurstbridge or serogroup Hurstbridge or *L. fainei*.

The person skilled in the art will be aware of nucleic acid hybridisation techniques which may be used to identify leptospire which are related to serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, in particular the various hybridisation stringencies which may be employed in such an identification procedure. For the purposes of the defining the level of stringency, a low stringency is defined herein as being a hybridisation and/or wash carried out in 6xSSC buffer, 0.1% (w/v) SDS at 28°C. Generally, the stringency is increased by reducing the concentration of SSC buffer, and/or increasing the concentration of SDS and/or increasing the temperature of the hybridisation and/or wash. Conditions for hybridisations and washes are well understood by one normally skilled in the art. For the purposes of clarification, of the parameters affecting hybridisation between nucleic acid molecules, reference is found in pages 2.10.8 to 2.10.16 of Ausubel *et al* (1987), which is

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

WO 98/40099

PCT/AU98/00145

- 20 -

herein incorporated by reference.

The person skilled in the art will appreciate that the nucleic acid molecules of the present invention may correspond to the naturally-occurring sequence or may differ by one or more  
5 nucleotide substitutions, deletions and/or additions. Accordingly, the present invention extends to rRNA genes and any isolated, synthetic or recombinant genes, oligonucleotides, mutants, derivatives, parts, fragments, homologues or analogues thereof which are at least useful as, for example, genetic probes, or primer sequences in the enzymatic or chemical synthesis of said gene, or in the generation of immunologically interactive recombinant  
10 molecules, or in the isolation or detection of a pathogenic *Leptospira* bacterium.

In a particular preferred embodiment, the serovar hurstbridge or serogroup Hurstbridge or *L. fainei* rRNA genetic sequence or a derivative, homologue or analogue thereof, is employed to identify similar genes from cells, tissues, or organ types of a host organism,  
15 in particular, the cells, tissues or organs of the urogenital tract including the bladder, uterus, fallopian tubes or kidney, or body fluids or exudates such as urine or cerebrospinal fluid, amongst others, which may be infected with a pathogenic *Leptospira* bacterium.

According to this embodiment, there is contemplated a method for identifying a related  
20 rRNA genetic sequence in a host organism which may be infected with a pathogenic *Leptospira* bacterium, said method comprising contacting cellular extract or nucleic acid sample obtained from said host organism with a hybridisation effective amount of a rRNA genetic sequence or a functional part thereof derived from serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, and then detecting said hybridisation. Accordingly, this  
25 embodiment of the present invention also relates to a method of identifying a serovar of *Leptospira* which is related to leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, in particular the leptospiral strain deposited with AGAL on 15 November, 1995 under Accession No. N95/69684.

30 Said rRNA genetic sequence may be labelled with a reporter molecule which is capable of

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

WO 98/40099

PCT/AU98/00145

- 21 -

giving an identifiable signal (eg. a radioisotope such as  $^{32}\text{P}$  or  $^{35}\text{S}$  or a biotinylated molecule).

An alternative method contemplated in the present invention involves hybridising two  
5 nucleic acid "primer molecules" of at least 15 nucleotides in length derived from the rRNA  
sequence of the invention or its complementary sequence to a nucleic acid "template  
molecule" derived from a cell, tissue or organ of a host human or other animal being tested  
for the presence of a pathogenic *Leptospira* bacterium, said template molecule herein  
defined as a related leptospiral 16S rRNA genetic sequence, or a functional part thereof, or  
10 its complementary sequence. Specific nucleic acid molecule copies of the template  
molecule are amplified enzymatically in a polymerase chain reaction. Methods for the  
isolation of said template molecule and for the polymerase chain reaction are known to  
those skilled in the art.

15 The nucleic acid primer molecules are generally single-stranded synthetic oligonucleotides  
although the present invention also contemplates other primers. According to this  
embodiment, the nucleic acid primer molecule consists of a combination of any of the  
nucleotides adenine, cytidine, guanine, thymidine, or inosine, or functional analogues or  
derivatives thereof, capable of being incorporated into a polynucleotide molecule.

20 Preferably, each nucleic acid primer molecule is any nucleotide sequence of at least 15  
nucleotides in length derived from, or complementary to the nucleotide sequence of serovar  
hurstbridge or serogroup Hurstbridge or *L. fainei* 16S rRNA or a derivative, homologue or  
analogue thereof. In a particularly preferred embodiment, at least one primer molecule is  
25 substantially the same as, or complementary to, nucleotide sequences set forth in SEQ ID  
NOs:2 and 3.

The nucleic acid template molecule may be in a recombinant form, in a virus particle,  
bacteriophage particle, yeast cell, animal cell, or a plant cell. Preferably, the related genetic  
30 sequence originates from a mammalian cell, tissue or organ, optionally infected with a

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

WO 98/40099

PCT/AU98/00145

- 22 -

pathogenic leptospiral bacterium such as serovar hurstbridge or serogroup Hurstbridge or *L. fainei*. More preferably, said mammalian cell, tissue or organ further originates from a human or a livestock or companion animal which is capable of being infected with said bacterium, in particular a livestock or companion animal selected from the list comprising  
5 pigs, bovines, sheep, goats, horses, deer, alpacas, dogs or cats, amongst others.

A further aspect of the present invention provides an immunologically interactive molecule prepared against one or more immunogens of a pathogenic *Leptospira* bacterium or derivative bacterium thereof which grows at temperatures from about 13°C to about 37°C  
10 and/or in the presence of at least 100µg/ml 8-azaguanine, preferably at least 150µg/ml 8-azaguanine, more preferably at least 200µg/ml 8-azaguanine and even more preferably at least 250µg/ml, or up to and including a concentration of 500µg/ml 8-azaguanine.

In a particularly preferred embodiment, the bacterium is the leptospire of the invention or  
15 a derivative bacterium thereof. In a most particularly preferred embodiment, said bacterium is the strain deposited with AGAL on 15 November, 1995 under AGAL Accession No. N95/69684 or a derivative bacterium thereof.

The term "immunologically interactive molecule" as used herein shall be taken to include  
20 polyclonal or monoclonal antibodies, or functional derivatives thereof, for example Fabs, SCABS (single-chain antibodies) or antibodies conjugated to an enzyme, radioactive or fluorescent tag, the only requirement being that said immunologically interactive molecule is capable of binding to an immunogen derived from or present in or present on the surface of a *Leptospira*, in particular serovar hurstbridge or serogroup Hurstbridge or *L. fainei*.

25 In an alternative embodiment, the present invention provides an immunologically interactive molecule prepared against one or more immunogens of a pathogenic *Leptospira* bacterium or derivative bacterium thereof which is capable of growing at temperatures of from about 13°C to about 37°C and/or in the presence of at least 100µg/ml 8-azaguanine,  
30 preferably at least 150µg/ml 8-azaguanine, more preferably at least 200µg/ml 8-azaguanine

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

WO 98/40099

PCT/AU98/00145

- 23 -

and even more preferably at least 250µg/ml, or up to and including a concentration of 500µg/ml 8-azaguanine, wherein at least one of said immunogens is a surface lipopolysaccharide molecule.

- 5 In a particularly preferred embodiment of the invention, said *Leptospira* bacterium is the serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or a derivative bacterium thereof. Most preferably, said bacterium is the strain deposited with AGAL on 15 November, 1995 under AGAL Accession No. N95/69684 or a derivative bacterium thereof.
- 10 In a related embodiment, the immunologically interactive molecule of the present invention may be prepared against an immunogen which mimics, or cross-reacts with a B cell or T cell epitope of a surface lipopolysaccharide molecule of a pathogenic *Leptospira* bacterium, preferably serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or a derivative bacterium thereof, more preferably the strain deposited with AGAL on 15 November, 1995
- 15 under AGAL Accession Number N95/69684.

- Conventional methods can be used to prepare the immunologically interactive molecules. For example, by using the bacterial strain or serovar of the present invention or an immunogen derived therefrom, polyclonal antisera or monoclonal antibodies can be made
- 20 using standard methods. As demonstrated herein, a mammal, (e.g., a mouse, hamster, or rabbit) can be immunised with an immunogenic form of serovar hurstbridge or serogroup Hurstbridge or *L. fainei* which elicits an antibody response in the mammal. Techniques for conferring immunogenicity on a surface protein or other molecule produced by the leptospire of the invention include conjugation to carriers or other techniques well known
- 25 in the art. For example, the bacterium can be administered in the presence of adjuvant. The progress of immunisation can be monitored by detection of antibody titres in plasma or serum. Standard ELISA or other immunoassay can be used with the immunogen as antigen to assess the levels of antibodies. Following immunisation, antisera can be obtained and, if desired IgG molecules corresponding to the polyclonal antibodies may be
- 30 isolated from the sera.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

WO 98/40099

PCT/AU98/00145

- 24 -

To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunised animal and fused with myeloma cells by standard somatic cell fusion procedures thus immortalising these cells and yielding hybridoma cells. Such techniques are well known in the art. For example, the hybridoma technique originally developed by Kohler and Milstein (1975) as well as other techniques such as the human B-cell hybridoma technique (Kozbor *et al.*, 1983), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, 1985), and screening of combinatorial antibody libraries (Huse *et al.*, 1989). Hybridoma cells can be screened immunochemically for production of antibodies which are specifically reactive with the polypeptide and monoclonal antibodies isolated.

As with all immunogenic compositions for eliciting antibodies, the immunogenically effective amounts of the immunogen must be determined empirically. Factors to be considered include the immunogenicity of the immunogen, whether or not it is to be complexed with or covalently attached to an adjuvant or carrier protein or other carrier and route of administration for the composition, i.e. intravenous, intramuscular, subcutaneous, *etc.*, and the number of immunising doses to be administered. Such factors are known in the vaccine art and it is well within the skill of immunologists to make such determinations without undue experimentation.

The term "antibody" as used herein, is intended to include fragments thereof which are also specifically reactive with a molecule which comprises, mimics, or cross-reacts with a B cell or T cell epitope of a surface lipopolysaccharide or surface polypeptide or other molecule produced by serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, in particular the strain deposited with AGAL under Accession Number N95/69684. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab')<sub>2</sub> fragments can be generated by treating antibody with pepsin. The resulting F(ab')<sub>2</sub> fragment can be treated to reduce disulfide bridges to produce Fab' fragments.

30

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

WO 98/40099

PCT/AU98/00145

- 25 -

It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies) directed to the first mentioned antibodies discussed above. Both the first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody. An antibody as contemplated herein includes any antibody specific to any immunogen of leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, in particular the strain deposited under AGAL Accession Number N95/69684. Preferably, said immunogen is a surface lipopolysaccharide molecule or a molecule which mimics a continuous or discontinuous B-cell or T-cell epitope of same.

10

The polyclonal, monoclonal or chimeric monoclonal antibodies can be used to detect the pathogenic bacterium of the invention or a derivative bacterium thereof in various biological materials, for example they can be used in an ELISA, radioimmunoassay or histochemical tests. Said antibodies are also useful in the detection of the isolated immunogen against which they are prepared, in either impure or pure form. Thus, the antibodies can be used to test for binding to the leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, or a derivative bacterium thereof in a sample or to test for binding to the isolated immunogen or to test for binding to any molecule which cross-reacts with a B cell or T cell epitope of same.

20

A wide range of immunoassay techniques are available as can be seen by reference to US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. These, of course, include both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.

25

Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilised on a solid substrate and the sample

30

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:44PM

WO 98/40099

PCT/AU98/00145

- 26 -

to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time and under conditions sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule.

In this case, the first antibody is raised to an immunogen of a pathogenic *Leptospira* bacterium, wherein said bacterium is preferred to be serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or a strain deposited with AGAL under Accession Number N95/69684 as described herein. More preferably, said first antibody is raised to an immunogen of said pathogenic *Leptospira* bacterium wherein, said immunogen is a surface lipopolysaccharide of the serovar hurstbridge or serogroup Hurstbridge or *L. fainei*.

The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention the sample is one which might contain serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or a derivative bacterium thereof or alternatively, an immunogen derived from said bacteria.

In the typical forward sandwich assay, a first antibody raised against serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or an immunogen thereof is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

WO 98/40099

PCT/AU98/00145

- 27 -

The binding processes are well-known in the art and generally consist of cross-linking, covalent binding or physically adsorption. the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes) and under suitable conditions (e.g. 25°C) to allow binding of any antigen present in the sample to the antibody. Following the incubation period, the reaction locus is washed and dried and incubated with a second antibody specific for a portion of the first antibody. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten.

10

An alternative method involves immobilising the target molecules in the biological sample and then exposing the immobilised target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detected by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

15

By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

20

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognised, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the

25

30

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

662221 32808660

WO 98/40099

PCT/AU98/00145

- 28 -

corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody-hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample. The term "reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in enzyme immunoassays (EIA), the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed. It will be readily apparent to the skilled technician how to vary the above assays and all such variations are encompassed by the present invention.

Accordingly, a further aspect of the present invention provides a method for the detection, identification or quantification of a pathogenic *Leptospira* bacterium or derivative bacterium thereof, wherein said method comprises the steps of incubating the material or

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

WO 98/40099

PCT/AU98/00145

- 29 -

bacteria derived therefrom with an antibody which recognises said bacteria or an immunogen derived therefrom for a time and under conditions sufficient for an antibody: immunogen or antibody; bacterium complex to form and subjecting said complex to a detecting means.

5

According to this aspect of the invention, the complex may be detected by using the bacterium or immunogen derived therefrom or the antibody molecule with a reporter molecule attached thereto. Alternatively, the complex may be detected by the addition of a second antibody labelled with a reporter molecule.

10

Preferably, the invention according to this aspect provides a method for the detection, identification or quantification of a pathogenic *Leptospira* bacterium or derivative bacterium thereof which is capable of growing in a medium as hereinbefore described, at temperatures of 13°C to 37°C and/or in the presence of at least 100µg/ml 8-azaguanine.

15 more preferably at least 150µg/ml 8-azaguanine, even more preferably at least 200µg/ml 8-azaguanine and most preferably at least 250µg/ml, or up to and including a concentration of 500µg/ml 8-azaguanine.

In a most particularly preferred embodiment, this aspect of the invention and the  
20 embodiments described therein relate to a method for the detection, identification or quantification of the leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, such as the strain deposited under AGAL Accession No. N95/69684.

According to this aspect of the invention, the material or bacteria derived therefrom is in  
25 a biological tissue or organ derived from a mammalian animal which is a host for a bacterium of the genus *Leptospira*, in particular serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or derivative bacterium thereof. Preferably, said mammalian animal is a human or a livestock or companion animal, in particular a livestock or companion animal selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpacas,  
30 dogs or cats, amongst others.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

WO 98/40099

PCT/AU98/00145

- 30 -

The biological sample to be tested may be any cell, tissue or organ which is capable of being infected with a bacterium of the genus *Leptospira*, in particular a cell, tissue or organ of the urogenital tract such as kidney, bladder, fallopian tube, uterus or endometrium, testes, or a body fluid or exudate such as, but not limited to urine or cerebrospinal fluid, amongst others. The present invention also contemplates the use of blood or blood-derived products as a biological sample suitable for the detection, identification or quantification of serovar hurstbridge or serogroup Hurstbridge or *L. fainei*.

A further aspect of the present invention contemplates a kit for the rapid and convenient assay of pathogenic *Leptospira* bacterium or derivative bacterium thereof in a biological sample, wherein said bacterium is capable of growing at temperatures from about 13°C to about 37°C and/or in the presence of at least 100µg/ml 8-azaguanine, preferably at least 150µg/ml 8-azaguanine, more preferably at least 200µg/ml 8-azaguanine and even more preferably at least 250µg/ml, or up to and including a concentration of 500µg/ml 8-azaguanine.

In a particularly preferred embodiment, the present invention contemplates a kit for the rapid and convenient assay of a pathogenic *Leptospira* bacterium or derivative bacterium thereof in a biological sample, wherein said bacterium is further characterised as leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or a derivative bacterium thereof according to any or all of the descriptions provided herein, for example the strain deposited under AGAL Accession No. N95/69684.

In one embodiment, said kit is compartmentalised to receive several first containers adapted to contain at least one immunogen each derived from the leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei* and several second containers adapted to contain an antibody molecule which binds to said pathogenic *Leptospira* bacterium, derivative bacterium thereof or immunogen derived therefrom, or alternatively, said second container contains an antibody molecule which binds to serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or a derivative bacterium thereof or immunogen derived therefrom. Preferably,

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

WO 98/40099

PCT/AU98/00145

- 31 -

said second container contains an antibody which binds to the serovar deposited with AGAL under Accession Number N95/69684, or an immunogen derived therefrom, in particular a surface lipopolysaccharide immunogen.

- 5 According to this embodiment of the present invention, said antibody molecule is optionally labelled with a reporter molecule capable of producing a detectable signal as hereinbefore described. If the first antibody molecule is not labelled with a reporter molecule, the kit also provides several third containers which contain a second antibody which recognises the first antibody and is conjugated to a reporter molecule. The reporter
- 10 molecule used in this kit may be an enzyme, a radio-isotope, a fluorescent molecule or bioluminescent molecule. amongst others.

- When the kit contains a first antibody or second antibody molecule which is conjugated to a reporter molecule which is an enzyme, then said kit also provides several fourth
- 15 containers which contain a specific molecule for said enzyme to facilitate detection of the immunogen: antibody complex or immunogen: antibody: antibody complex.

- Optionally, the first, second, third and fourth containers of said kit may be colour-coded for ease-of-use.

- 20 In an exemplified use of the subject kit, a control reaction is carried out in which the contents of the first container are contact with the contents of the second container for a time and under conditions sufficient for an immunogen:antibody complex to form in said first container. At the same time the sample to be tested is contacted with the contents of
- 25 the second container for a time and under conditions sufficient for an immunogen:antibody complex to form in said second container. If the antibody of the second container provided is not labelled with a reporter molecule, then the complexes produced in said first and second containers are contacted with the antibody of the third container for a time and under conditions sufficient for a tertiary immunogen:antibody:antibody complex to form.
- 30 The immunogen:antibody complex of immunogen:antibody:antibody complex is then

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

WO 98/40099

PCT/AU98/00145

- 32 -

subjected to a detecting means as hereinbefore described. In analysing the results obtained using said kit, the control reaction carried out in said first container should always provide a positive result upon which to compare the results obtained in said second container which contains the test sample.

5

In an alternative embodiment, the present invention contemplates a kit for the rapid and convenient assay of leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei* or a derivative bacterium thereof in a biological sample, wherein said kit is compartmentalised to receive several first containers adapted to contain two non-  
10 complementary primer molecules of at least 10 nucleotides, preferably at least 15 nucleotides and more preferably, at least 22 nucleotides in length. According to this embodiment, it is preferred that at least one of the first primer molecules is substantially identical to a region of the nucleotide sequence set forth in any one of SEQ ID NOs:1-7, more preferably any one of SEQ ID NOs:1-2 or 4-7 or a complement, or a derivative,  
15 homologue or analogue thereof and the second of said primer molecules is substantially identical to the complement of a region of the sequence set forth in SEQ ID NO:1 or a derivative, homologue or analogue thereof. Those skilled in the art will be aware of suitable combinations of nucleic acid primer molecules for the performance of this aspect of the present invention.

20

In a particularly preferred embodiment, the primer molecules are utilised as primer pairs, more preferably comprising SEQ ID NOs: 2 and 3 or primers LU and rLP (Table 10) or primers C and INT rLP (Table 10) or primers which are at least 80% identical thereto.

25 According to this embodiment, said kit also contains several second containers adapted to contain a reaction mixture comprising buffer and salt solution either ready-for-use or in concentrated form and several third containers adapted to contain an enzyme suitable for use in a nucleic acid hybridisation reaction or a polymerase chain reaction, for example any heat stable DNA polymerase enzyme, in particular *Thermophilus aquaticus* TaqI, or similar  
30 enzyme. Optionally, the first, second and third containers of said kit maybe colour coded

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

WO 98/40099

PCT/AU98/00145

- 33 -

for ease-of-use.

For the purposes of this embodiment of the present invention, the biological sample may be any cell, tissue, organ, body fluid or exudate of a mammalian animal which is capable of carrying a serovar of a pathogenic *Leptospira* bacterium of the invention, including for example any cell, tissue or organ of the urogenital tract, bladder, kidney, uterus, endometrium, testes or fallopian tube or a body fluid or exudate such as urine or cerebrospinal fluid, amongst others. The invention also contemplates the use of blood as a biological sample which is useful for the present purpose. Alternatively, or in addition to the foregoing examples of suitable biological samples, it is also possible to use a nucleic acid extract obtained from said cell, tissue or organ sample. Preferably, said biological sample originates from a livestock animal such as a human or a livestock or companion animal, in particular a livestock or companion animal selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpacas, dogs or cats, amongst others.

In an exemplified use of the subject kit described in this embodiment, a test sample reaction is carried out wherein the contents of the first, second and third containers are combined and a biological sample to be tested is added thereto. A negative control reaction may also be set up in which no biological sample is added to the reaction mixture. The test sample and negative control reactions are incubated for a time and under conditions sufficient for the amplification of DNA sequences which originate from the subject bacterium to occur.

A further aspect of the present invention contemplates a diagnostic test for the identification of a *Leptospira* pathogen in a biological sample using the methods, reagents and kits of the present invention as hereinbefore defined. Particularly preferred diagnostic assays are based on the serological detection of bacteria of the serogroup Hurstbridge using MAT or alternatively, the genetic detection of bacteria belonging the same species *L. fainei* using nucleic acid-based hybridisation and/or amplification reactions.

The present invention also extends to compositions comprising isolated recombinant

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

WO 98/40099

PCT/AU98/00145

- 34 -

polypeptide immunogens derived from a leptospiral bacterium and immunologically interactive molecules thereto, such as antibodies and serum comprising same, wherein said leptospiral bacterium belongs to the same serogroup as serogroup Hurstbridge or to the same serovar as serovar hurstbridge.

5

Accordingly, a still further aspect of the present invention contemplates a composition comprising:

1. one or more immunogens which are immunologically cross-reactive with a cellular component of a pathogenic *Leptospira* bacterium belonging to serogroup Hurstbridge or derivative bacterium thereof; and
2. one or more pharmaceutically or veterinarily acceptable carriers, adjuvants and/or diluents.

10

Alternatively, the composition comprises:

1. an antibody molecule or sera comprising same which is capable of binding to one or more antigens of a pathogenic *Leptospira* bacterium belonging to serogroup Hurstbridge or derivative bacterium thereof; and
  2. one or more pharmaceutically or veterinarily acceptable carriers, adjuvants and/or diluents.
- The antibody molecule may be a monoclonal or polyclonal antibody, immunoglobulin fraction, Fab or recombinant single-chain antibody molecule or an immunological equivalent thereof.

15

20

Preferably, the composition according to these embodiments is a vaccine preparation. In a more preferred embodiment, said compositions induce humeral immunity against serovar hurstbridge or serogroup Hurstbridge or *L. fainei* when administered to a human or animal subject. In a most particularly preferred embodiment, said composition induces humoral immunity against the leptospire deposited with AGAL under Accession Number N95/69684.

30

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

WO 98/40099

PCT/AU98/00145

- 35 -

In a preferred embodiment, the immunogen or antigen according to this aspect of the invention is immunologically cross-reactive with a bacterium characterised according to any or all of the descriptions provided herein as leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, in particular the leptospiral strain deposited with AGAL under  
5 Accession Number N95/69684.

In a more preferred embodiment, at least one of said immunogens or antigens is a surface lipopolysaccharide.

10 According to this aspect of the present invention, the immunogen component of an effective composition may also comprise a complete, attenuated leptospiral serovar hurstbridge or serogroup Hurstbridge or *L. fainei* which has been pre-treated to render it non-infectious and predominantly asymptomatic. Methods for attenuating said leptospiral serovar include, but are not limited to formalin-killing, heat-killing, irradiation or genetic  
15 modification to remove genetic material related to pathogenesis.

The compositions of the present invention are contemplated to exhibit excellent therapeutic activity, for example, in the prevention of diseases associated with infection by leptospiral pathogens such as serovar hurstbridge or serogroup Hurstbridge or *L. fainei*, in particular  
20 reproductive disease. Preferably, said composition is effective in mediating an immune response when administered to a mammalian animal, in particular to a human or a livestock or companion animal, such as a livestock or companion animal selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpacas, dogs or cats, amongst others.

25

The term "mediating an immune response" as used herein is defined in its broadest context to include the elicitation of T-cell activation by an immunogen and/or the generation, by B-cells, of neutralising antibodies which cross-react with one or more molecules encoded by a pathogenic serovar of *Leptospira* belonging to serogroup Hurstbridge as described  
30 herein or a derivative bacterium thereof. In particular, said neutralising antibodies cross-

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:43PM

662221 "9308260

WO 98/40099

PCT/AU98/00145

- 36 -

react with one or more molecules encoded by serovar hurstbridge or derivative bacterium thereof.

The composition may be administered in a convenient manner such as by the oral,  
5 intravenous (where water soluble), intramuscular, subcutaneous, intranasal, intradermal or  
suppository routes or implanting (eg using slow release molecules). Depending on the  
route of administration, the immunogens contained therein may be required to be coated  
in a material to protect them from the action of enzymes, acids and other natural conditions  
which otherwise might inactivate said immunogen. In order to administer the composition  
10 by other than parenteral administration, they will be coated by, or administered with, a  
material to prevent its inactivation. For example, the immunogen may be administered in  
an adjuvant, co-administered with enzyme inhibitors or in liposomes. "Adjuvant" as used  
herein is to be taken in its broadest sense and includes any immune-stimulating compound  
such as a cytokine. Adjuvants contemplated herein include resorcinols, non-ionic  
15 surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether.  
Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP)  
and trasylol. Liposomes include water-in-oil-in-water emulsions as well as conventional  
liposomes.

20 The composition of the present invention may also be administered parenterally or intra  
peritoneally. Dispersions of the immunogen component can also be prepared in glycerol,  
liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions  
of storage and use, these preparations contain a preservative to prevent the growth of  
microorganisms.

25

The forms suitable for injectable use include sterile aqueous solutions (where water  
soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile  
injectable solutions or dispersion. In all cases the form must be sterile and must be fluid  
to the extent that easy syringeability exists. It must be stable under the conditions of  
30 manufacture and storage and must be preserved against the contaminating action of

WO 98/40099

PCT/AU98/00145

- 37 -

microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating  
5 such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged  
10 absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the immunogen of the present  
15 invention in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by heat-sterilisation, irradiation or other suitable sterilisation means. Generally, dispersions are prepared by incorporating the various sterilised active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the  
20 case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

25 When immunogens are suitably protected as described above, the protected immunogen may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral administration, the protected immunogen may be incorporated with excipients and used in  
30 the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups,

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:42PM

WO 98/40099

PCT/AU98/00145

- 38 -

wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of immunogen in such compositions is such that effective  
5 immunisation will be achieved with between one and five doses of said vaccine.

The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the  
10 like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For  
15 instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the immunogen of  
20 the present invention may be incorporated into sustained-release preparations and formulations.

As used herein "pharmaceutically acceptable or veterinarily acceptable carrier and/or diluent" includes any and all solvents, dispersion media, coatings, antibacterial and  
25 antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

30

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:42PM



WO 98/40099

PCT/AU98/00145

- 40 -

In the Figures:

Figure 1 is a copy of a photographic representation of an electron micrograph of a bacterium belonging to serovar hurstbridge or serogroup Hurstbridge or *L. fainei*.  
5 *leptospira* strain BUT6 was examined by transmission electron microscopy using a Philips CM12 STEM electron microscope, employing negative staining with 2% phosphotungstic acid at a final magnification of 9,450X. The bar shows 1µm. Bacterial cells are approximately 12µm in length and 0.2µm in diameter and exhibit the typical helical or spiral morphology which is characteristic of *Leptospira*.

10

Figure 2 is a schematic representation showing the alignment of a 200bp region of the rRNA gene sequences of *L. fainei* (derived from SEQ ID NO:1) to the rRNA gene sequences of other *Leptospira* serovars, including *L. inadai* serovar lyme (SEQ ID NO:8),  
15 *L. meyeri* serovar ranarum (SEQ ID NO:9), *L. weilii* serovar celledoni (SEQ ID NO:10), *L. santarosii* serovar shermani (SEQ ID NO:11), *L. borgpetersenii* serovar javanica (SEQ ID NO:12), *L. kirschneri* serovar cynopteri (SEQ ID NO:13) and *L. interrogans* serovar icterohaemorrhagiae (SEQ ID NO:14). Asterisks indicate variable nucleotide residues. Base numbering is indicated at the top of the alignment.

20

### EXAMPLE 1

#### General strategy and selection of swine herds for culture

Three swine herds in Victoria and New South Wales were selected for culture, all  
25 serologically positive to *Leptospira interrogans* serovar bratislava. *Leptospira* bacteria had been visualised in each herd by immunofluorescent staining of tissues, despite a lack of serological evidence of infection with the known Australian pig leptospiral serovars, pomona and tarassovi. Cultures were established from uterus, fallopian tube and kidney of each animal. The objective was to maximise the chance of isolating serovar bratislava  
30 by culturing from both baconer-age gilts and sows.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:42PM

WO 98/40099

PCT/AU98/00145

- 41 -

The sample size was limited to 30 cultures for each animal or less. The culture program involved the use of an initial 24 culture tubes for each animal: three tissues, four antibiotic combinations, and two dilutions.

5

## EXAMPLE 2

### Collection of tissues for culture

Swine herds were selected according to Example 1. Tissues for culture were collected from  
10 animals at the Hurstbridge abattoir (Herds A and B) and the Altona abattoir (Herd C).  
Bladders were tied off with cable ties at the point of removal and uterus with fallopian  
tubes, and kidneys, were collected in sterile bags. Blood was also collected at the point of  
slaughter and matched with tissue samples. Pigs were identified at the point of slaughter  
by individual tattoo.

15

## EXAMPLE 3

### Bacterial Cultures

Tissue samples obtained as described in the preceding Examples were processed as soon  
20 as possible to limit the degree of autolysis. Fallopian tube segments, uterus endometrial  
scrapings and kidney samples were homogenised in phosphate-buffered albumin to protect  
leptospire then diluted to a final concentration of 1:100 prior to inoculating two 7.5 ml  
volumes of culture medium with one and five drops respectively. Samples were incubated  
at 30°C for up to 6 months and examined at intervals of approximately two to three weeks.  
25 Four different formulations of Tween 40/80 semisolid media were used, with different  
combinations of antibiotics, according to a matrix shown in Table 1.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:42PM

WO 98/40099

PCT/AU98/00145

- 42 -

TABLE 1

Matrix of antibiotic combinations used in the culture program designed to isolate *Leptospira interrogans* serovar bratislava.

Medium	5-Fluorouracil	Rifampicin	Amphotericin B	Naladixic Acid
M1	100µg/ml	NONE	NONE	NONE
M2	200µg/ml	NONE	NONE	NONE
M3	300µg/ml	NONE	NONE	20µg/ml
M4	100µg/ml	10µg/ml	2µg/ml	NONE

Cultures were established from 27 sows and gilts, 24 of which were from the three target herds (Table 2). Leptospires were observed in six cultures derived from five animals in two of the three target herds (B and C). Isolation was achieved in five cases, as shown in Table 3.

Structures similar to non-motile leptospires were observed in several cultures from herd A and appeared typical of bratislava when first observed in cultures. However, no motile leptospires developed from these cultures and isolation was not achieved. The identity of these possible leptospires could not be confirmed.

Four isolates of an organism from three sows were obtained from herd B. Isolates from herd B appeared as typical leptospires under both dark ground microscopy and transmission electron microscopy. Leptospires were also observed in two cultures from Herd C but only one isolate was obtained (Table 3).

#### EXAMPLE 4

##### Microscopic agglutination test (MAT)

The microscopic agglutination test (MAT) (Cole *et al.*, 1973) was performed using serovar hurstbridge isolate No. 6 (Table 3) as the live or reference antigen. Sera were typically

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:42PM

WO 98/40099

PCT/AU98/00145

- 43 -

tested at final dilutions (including antigen) from 1/32 to 1/256 or above. Rabbit antiserum to each serovar tested was included on each microtitre plate as a positive control. Titres were expressed as the reciprocal of the final serum dilution (including the volume of antigen) at which agglutination of 50% or more was observed.

5

The herd B isolate (Table 3) characterised according to its agglutination with antisera against a range of leptospiral pathogens. These isolates were not agglutinated to high titre by antisera against bratislava, pomona, tarassovi, hardjobovis, copenhageni or a number of other pathogenic serovars. The herd B organism was found to autoagglutinate strongly, and the results of these agglutination experiments were therefore difficult to read.

10

Isolate 1 from herd B was sent to the International Leptospirosis Reference Laboratory in Brisbane, Australia for confirmation of lack of agglutination by antisera to known leptospiral pathogens. It was also demonstrated that the isolate grew persistently at 13°C, and in the presence of 8-azaguanine, implying that it was a saprophyte and not a pathogen.

15

The isolate from Herd C failed to agglutinate with antisera to a number of known pathogenic leptospire (Table 4). However it agglutinated to high titre with rabbit antiserum raised against the Herd B isolate (Table 4). This indicates that it is probably the same organism. The Herd C isolate showed no autoagglutination when first obtained, unlike the isolates from Herd B.

20

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:42PM

WO 98/40099

PCT/AU98/00145

- 44 -

TABLE 2

Pigs from which tissues were cultured in an effort to isolate serovar bratislava.

Pig Number	Abattoir	Type and Age of Pig	Herd of Origin	Date of Culture
1	Hurstbridge	Gilt	A	20/10/93
2	Hurstbridge	Gilt	A	26/10/93
3	Hurstbridge	Gilt	A	26/10/93
4	Hurstbridge	Gilt	A	3/11/93
5	Hurstbridge	Gilt	A	3/11/93
6	Hurstbridge	Sow	A	4/11/93
7	Hurstbridge	Sow	N.S.W. herd	4/11/93
8	Hurstbridge	Sow	A	4/11/93
9	Hurstbridge	Sow	N.S.W. herd	23/11/93
10	Hurstbridge	Sow	Victorian herd	23/11/93
11 <sup>1</sup>	Hurstbridge	Gilt	B	2/1/94
12	Hurstbridge	Gilt	B	21/1/94
13	Hurstbridge	Gilt	B	21/1/94
14	Hurstbridge	Gilt	B	21/1/94
15	Hurstbridge	Gilt	B	21/1/94
16 <sup>2</sup>	Hurstbridge	Sow	B	4/2/94
17 <sup>2</sup>	Hurstbridge	Sow	B	4/2/94
18 <sup>2</sup>	Hurstbridge	Sow	B	4/2/94
19	Hurstbridge	Sow	B	4/2/94
20	Hurstbridge	Sow	B	4/2/94
21	Hurstbridge	Sow	B	4/2/94
22	Altona	Sow	C	13/4/94
23	Altona	Sow	C	13/4/94
24 <sup>2</sup>	Altona	Young sow	C	4/5/94
25 <sup>2</sup>	Altona	Young sow	C	4/5/94
26	Altona	Young sow	C	4/5/94
27	Altona	Young sow	C	4/5/94

<sup>1</sup>Discarded early as cultures incorrectly inoculated.<sup>2</sup>Leptospiral Isolates were obtained from these pigs. See Table 3.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:42PM

WO 98/40099

PCT/AU98/00145

-45-

**TABLE 3**  
**Observation of Leptospires in Cultures.**

Number	Herd	Pig No.	MAT Titre to bratislava	Pig Type	Date Cultured	Date First Observed	Weeks of Culture	Tissue	Isolated	Remarks
1	B	16	128	Sow	4/2/94	16/2/94	2	Uterus	Yes	These isolates appear to be identical.
2	B	16	128	Sow	4/2/94	20/2/94	2	Kidney	Yes	
3	B	17	32	Sow	4/2/94	23/3/94	7	Kidney	Yes	
4	B	18	64	Sow	4/2/94	26/4/94	11	Uterus	Yes	
5	C	25	<32	Young sow	4/5/94	28/6/94	8	Uterus	No	Typical leptospire, lost in culture.
6	C	24	<32	Young sow	4/5/94	31/8/94	17	Kidney	Yes	Typical leptospire. Agglutinated by antiserum to isolate 1.

5

10

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:42PM

SECRET " 92302250

WO 98/40099

PCT/AU98/00145

- 46 -

TABLE 4

Microscopic agglutination test titres given by isolate 6 from Herd C  
with some high titre rabbit antisera.

Rabbit Antiserum against:	Agglutination Titre
bratislava strain 834	<4
bratislava strain Jez	<4
pomona	32
tarassovi	64
isolate 1 from Herd B	≥8192

## EXAMPLE 5

## MAT titres in human leptospirosis patients

723 sera derived from human subjects which had been submitted to Monash University, Victoria, Australia for diagnostic leptospirosis serology were also tested by the MAT for antibodies to serovar hurstbridge or serogroup Hurstbridge. Approximately 79% of the sera were obtained from males. Most sera were believed to be derived from patients exhibiting symptoms consistent with leptospirosis.

The MAT were initially conducted at Monash University using the *Leptospira borgpetersenii* serovars ballum, hardjobovis and tarassovi and the *L. interrogans* serovars australis, copenhageni and pomona as antigens. The MAT for these serovars differed from the MAT for serovar hurstbridge or serogroup Hurstbridge as described in Example 4 in the following particulars: Firstly, agglutination was observed microscopically after transferring a loop of suspension from each well of a microtitre plate onto a microscope slide. Secondly, the first serum dilution in the dilution series was 1/50.

In the present study, MAT for serovar hurstbridge or serogroup Hurstbridge was performed as described in Example 4 using these 723 serum samples.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:42PM

WO 98/40099

PCT/AU98/00145

- 47 -

Additionally, a control group of sera obtained from 62 staff at the Victorian Institute of Animal Science (VIAS), Victoria, Australia was also subjected to MAT for serovar hurstbridge or serogroup Hurstbridge antibodies. The 62 control sera came from 27 males and 35 females.

5

As shown in Table 5, MAT titres in the two groups of sera were strikingly different. Of the 723 diagnostic sera tested, 7.2% of sera had titres of  $>512$  and 13.4% of sera had titres of  $>128$ . In contrast, all 62 sera in the control group from VIAS had MAT titres of 32 or less. The difference between the groups in titres of  $>128$  was highly significant ( $\chi^2 = 9.55$ ,  
10  $df=1.0$ ;  $p < 0.01$ ). Analysis of postal area codes showed that patients with MAT titres to serovar hurstbridge or serogroup Hurstbridge came predominantly from dairying and pig-producing areas of Victoria.

The prevalence of high titres to each serovar in the diagnostic sera is shown in Table 6.  
15 About 7% of the sera gave MAT titres of  $\geq 400$  to serovar hardjobovis and a similar percentage gave MAT titres of  $\geq 512$  to serovar hurstbridge or serogroup Hurstbridge. In contrast, there were far fewer titres of  $\geq 400$  to the other serovars.

TABLE 5

20 **MAT titres to serovar hurstbridge in human sera submitted for leptospirosis diagnostic testing compared with a control population**

25	MAT titre	Test Group			Control Group		
		Male	Female	Total	Male	Female	Total
	$\leq 32$	448	129	577	28	35	62
	64	37	12	49	0	0	0
	128-256	38	7	45	0	0	0
30	$\geq 512$	45	7	52	0	0	0
	Total	568	155	723	28	35	62

SUBSTITUTE SHEET (RULE 26)

WO 98/40099

PCT/AU98/00145

- 48 -

TABLE 6

**MAT titres of  $\geq 400$  to different leptospiral serovars in 723 human sera  
submitted for leptospirosis diagnostic testing.**

5	Serovar	No sera with titres $\geq 400$	% sera with titres $\geq 400$
10	australis	1	0.1
	ballum	2	0.3
	copenhageni	1	0.1
	hardjobovis	49	6.8
	hurstbridge (>512)	52	7.2
	pomona	0	0.0
15	tarassovi	3	0.4

## EXAMPLE 6

20      **Relationship between sow reproductive performance  
and titres to serovar hurstbridge or serogroup Hurstbridge**

A study was performed of the relationships between reproductive performance and titres to serovar hurstbridge or serogroup Hurstbridge in a New South Wales herd. Serum samples were obtained at random from a total of 468 mixed parity sows, and serum samples were tested by the MAT for serovar hurstbridge or serogroup Hurstbridge (Example 4). Titres obtained were compared with the full reproductive histories of the sampled animals. The 468 animals sampled had been mated a total of 1484 times. The outcomes of different matings from the same sow were related to the same serological result.

30      Table 7 demonstrates a highly significant association between MAT titres to serovar hurstbridge and returns to service in sows in Herd B (Examples 1 and 2). Overall, sows with titres to hurstbridge were significantly more likely to return to service than serologically negative sows, an overall difference of 4.3% in farrowing rate. However, a

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:41PM

60808260



WO 98/40099

PCT/AU98/00145

- 50 -

mating was significantly longer ( $p < 0.01$ ) in animals of this group having higher titres to serovar hurstbridge or serogroup Hurstbridge (Table 9).

5

**TABLE 8**

**Relationship between MAT titres to serovar hurstbridge or serogroup Hurstbridge and percentage of foetal deaths, in sows with completed pregnancies.**

10

<b>MAT titre hurstbridge</b>	<b>&lt;32</b>	<b>32</b>	<b>64</b>	<b>128</b>
<b>Mean % foetal deaths</b>	<b>3.5</b>	<b>2.1</b>	<b>5.3</b>	<b>25.0</b>
<b>Number of sows</b>	<b>53</b>	<b>35</b>	<b>24</b>	<b>4</b>

15

20

**TABLE 9**

**Increased weaning-to-mating interval associated with MAT titres of  $\geq 64$  to serovar hurstbridge or serogroup Hurstbridge.**

25

<b>MAT titre</b>	<b>&lt;64</b>	<b><math>\geq 64</math></b>
<b>Weaning to mating (days)</b>	<b>5.0</b>	<b>5.7</b>

30

WO 98/40099

PCT/AU98/00145

- 51 -

**EXAMPLE 7****Extracting DNA of Pathogenic Leptospire from Pig Kidney  
for Polymerase Chain Reaction**

- 5 Five percent suspensions of Chelex 100 resin (Bio-Rad, 100-200 mesh sodium form) were prepared by adding resin to sterile distilled water while stirring, then autoclaved.

Samples of approximately 0.2 g of kidney were treated for 5 min. in a stomacher, with 2 ml of sterile phosphate buffered saline. A 0.5 ml volume of the resulting suspension was removed to a microfuge tube, and 50  $\mu$ l was transferred to another tube containing 200  $\mu$ l of Chelex 100 suspension. The second tube was vortexed (5 sec.) and incubated at room temperature for 30 min., vortexed again and incubated at 100°C for 8 min., vortexed again and centrifuged in a microfuge at 13,000 r.p.m for 3 min.

- 15 The supernatant was removed and further purified by ethanol precipitation as follows: To a microfuge tube was added 10  $\mu$ l 3M sodium acetate, 275  $\mu$ l 100% ethanol, and 100  $\mu$ l of Chelex 100 supernatant. The suspension was stored overnight at -20°C. The supernatant was removed, 500  $\mu$ l 70% ethanol was added, and the resulting pellet was washed, with a further microfuging at 13,000 r.p.m. for 15 m. The supernatant was then removed, and dried by evaporation at room temperature for 1 h.

The pellet was resuspended in 40  $\mu$ l of TE buffer (10 mM Tris HCl, 1 mM EDTA, pH 8.0).

**EXAMPLE 8**

- 25 **Identifying Pathogenic Leptospire by Gene Sequences of PCR Products**

PCR products of about 1.4 kb. corresponding to most of the rRNA gene sequences of a number of leptospiral serovars, were generated using oligonucleotide primers 27F and 1392R (Table 10) from conserved regions of the gene. The DNA products were purified using a Wizard™ PCR clean-up kit. The eluted products were then electrophoresed on 1%(w/v) low-melting-temperature agarose gels and the desired bands were excised using

**SUBSTITUTE SHEET (RULE 26)**

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:41PM

WO 98/40099

PCT/AU98/00145

- 52 -

a scalpel blade and further purified using a Wizard clean-up kit.

TABLE 10

## Amplification and sequencing primers

PRIMER	NUCLEOTIDE SEQUENCE (5'→3') <sup>1</sup>
27F <sup>4</sup>	CATGGATCCAGAGTTTGATCMTGGCTCAG
530F <sup>4</sup>	GTGCCAGCMGCCGCGG
926F <sup>4</sup>	AAACTYAAAKGAATTGACGG
LU <sup>5</sup>	CGGCGCGTCTTAAACATG
C <sup>2</sup>	CAAGTCAAGCGGAGTAGCAA
1392R <sup>4</sup>	ACGGGCGGTGTGTRC
1100R <sup>4</sup>	GGGTTGCGCTCGTTG
660R <sup>3</sup>	ITCACCCTACACCTGGAA
519R <sup>4</sup>	GWATTACCGCGGCKGCTG
rLP <sup>5</sup>	ACCATCATCACATYGCTGC
B <sup>2</sup>	TTCCCCCATTGAGCAAGATT
INT rLP <sup>5</sup>	TTATTTTCCCTGCTTACTGAAC

1. A= adenine; C=cytosine; G=guanine; T=thymine; Y=C or T; R=A or G; K=G or T; M=A or C; W=A or T.

2. Primers B and C were disclosed by Merien *et al* (1992).

3. This primer was disclosed originally by Hookey (1992).

4. These primers are disclosed by Lane (1991).

5. These primers are disclosed by Perolat *et al* (1998).

25 Nucleotide sequences of the amplified DNAs were obtained on a Biosystems Model 373A DNA Sequencer, using overlapping forward primers (27F, 530F, 926F in Table 10) and reverse primers (1392R, 1100R, 660R, 519R in Table 10).

30 Nucleotide sequencing was attempted on the genes from serovars bratislava, hardjobovis, copenhageni, tarassovi and australis. A partial gene sequence was also obtained using the

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:41PM

WO 98/40099

PCT/AU98/00145

- 53 -

27F primer for two isolates (1 and 2) of the leptospire cultured from Herd B.

Complete 16S ribosomal RNA gene sequences were obtained for serovars bratislava, hardjobovis, copenhageni and tarassovi. These were compared with published sequences from serovars pomona, canicola, icterohaemorrhagiae and several others, available through GENE BANK. A partial sequence derived for *L. biflexa* serovar patoc corresponded to a sequence in GENE BANK.

Nucleotide sequence homology data between the herd B leptospire and a number of leptospiral serovars is shown in Table 11. The results of this and more detailed comparison indicate that:

- (a) the new isolate falls within the pathogenic grouping and not the saprophytic grouping of leptospires; (b) the new isolate nevertheless is not bratislava, pomona or tarassovi; and (c) the new isolate is most similar, with respect to rRNA gene sequence identity, to *L. inadai* serovar lyme.

TABLE 11

Homology of the sequence of the region of the 16S ribosomal RNA gene from base 51 to base 199 between the leptospire isolated from herd B and a number of other serovars.

Group	Species	Serovar	Percentage Homology
Pathogens	<i>L. interrogans</i>	bratislava	87.6
		pomona	90.2
		canicola	88.3
	<i>L. inadai</i>	lyme	96.6
Saprophyte	<i>L. biflexa</i>	patoc	75.2

In a further series of experiments to characterise the leptospire of the invention, leptospiral DNA was extracted from pig kidneys as described in Example 5 and rRNA gene sequences

WO 98/40099

PCT/AU98/00145

- 54 -

were then amplified using the polymerase chain reaction (PCR) for detecting leptospiral DNA method described in Example 10. In these experiments, a positive control consisting of tissue extract comprising DNA and seeded with  $10^5$  /ml organisms of serovar pomona was included in each reaction series. The extracted DNA was amplified in a reaction mixture comprising 2.5  $\mu$ l 10x Taq buffer with 15mM  $MgCl_2$ , 2.5  $\mu$ l dNTPs (Promega), 0.5  $\mu$ l each of forward and reverse primers (50 pmol/ $\mu$ l), 1 u Taq DNA polymerase (Promega, typically 5 unit/ $\mu$ l) 8.5  $\mu$ l sterile distilled water, and 10  $\mu$ l DNA sample. The primers used in the amplification reactions are listed in Table 10. PCR reactions were performed using a Perkin-Elmer GeneAmp PCR System 2400 using the following conditions: one cycle at 94°C for 3 min, 56°C for 1.5 mins 72°C for 2 min; twenty nine cycles at 94°C for 1 min, 56°C for 1.5 min, 72°C for 2 min; and one cycle at 94°C for 1 min, 56°C for 1.5 min, 72°C for 10 min. Amplification products were visualised after electrophoresis on 1%(w/v) agarose gels containing ethidium bromide. Each PCR product obtained was sequenced in the forward direction and in the reverse direction using a series of primers (Table 10). Consensus sequences were derived, using the results of both forward and reverse sequencing.

The nucleotide sequences of an approximately 200 base-pair region of the amplified rRNA genes of several leptospires, corresponding to nucleotide positions 139-334 of the *Escherichia coli* rRNA gene, were compared to identify variable regions between serovars. Of the 200 bases analysed, 25 nucleotides were found to vary among leptospires. The sequences in the region studied do not vary sufficiently for all pathogenic leptospiral serovars to be distinguished. However, the differences are sufficient to differentiate nine pathogenic species. A data base of sequence information was collected comprising the rRNA gene sequence set forth in SEQ ID NO:1 and rRNA sequences derived from the following eight representative serovars of eight leptospiral species: serovar javanica (*L. borpetersenii*), serovar lyme (*L. inadai*), serovar cynopteri (*L. kirschneri*), serovar ranarum (*L. meyeri*), serovar panama (*L. noguchii*), serovar shermani (*L. saratosa*), serovar celledoni (*L. weilii*) and serovar icterohaemorrhagiae (*L. interrogans*).

Each of these representative sequences were different. Homology between them varied

SUBSTITUTE SHEET (RULE 26)

WO 98/40099

PCT/AU98/00145

- 55 -

from 89.5% (21/200 bases different) to 99.5% (1/200 different). Serovar hurstbridge and *L. inadai* formed a group which is distinct from the other species examined, on the basis of rRNA gene sequence homology. Additionally, nucleotide sequences from these two species could be clearly differentiated from one another.

5

### EXAMPLE 9

#### Polymerase chain reaction specific for pathogenic leptospires

PCR to detect pathogenic leptospires in culture samples was based on the method of  
10 detection of the 16S ribosomal RNA gene as described by Hookey (1992) using both the oligonucleotide primers described therein. It was found necessary to adjust the annealing temperatures used to achieve the published levels of specificity.

Samples for PCR were heated before testing, at 100°C for 10 minutes. The typical PCR  
15 reaction volume of 50 µl consisted of 1 µl sample, 5 µl buffer concentrate (giving final concentrations of 0.1M Tris-HCl, pH 9.0, 0.5M KCl, 0. 1% gelatin, 15 mM MgCl<sub>2</sub>, 1% Triton X-100), 5 µl dNTPs (each at final concentrations of 0.25 mM), 1 µl forward primer and 1 µl reverse primer at appropriate dilutions in water, 1 µl Taq DNA polymerase 1/5 in diluting buffer, and 36 µl water. The enzyme diluting buffer consisted of 10 mM Tris-HCl  
20 pH 7.5, 300 mM KCl, 1 mM DAT., 0.1 mM EDTA, 500 µg/ml bovine albumin, 50% (v/v) glycerol and 0. 1% (v/v) Triton X-100.

PCR was performed in a Perkin Elmer Cetus GeneAmp PCR System 9600. PCR  
conditions using the primers of Hookey (1992) were 35 cycles of 94°C (10 seconds), 59°C  
25 (10 seconds) and 72°C (10 seconds).

PCR was shown to be a reproducible method for detecting leptospires in culture. After  
modification of annealing conditions, PCR using the primers of Hookey (1992) detected  
all five isolated strains of serovar hurstbridge (Table 3) and the pathogenic leptospires  
30 bratislava, tarassovi and pomona. However, *Leptospira biflexa* serovar patoc, a representative saprophytic leptospire, was negative in this assay.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:41PM

WO 98/40099

PCT/AU98/00145

- 56 -

**EXAMPLE 10****Polymerase chain reaction for detecting leptospire in serum**

Oligonucleotide primers were designed to allow the amplification of part of the 16S ribosomal RNA (rRNA) gene from leptospira samples or isolated nucleic acid samples derived therefrom. A nested PCR was used to maximise sensitivity. Nested PCR is well-known to those skilled in the art and the general strategy is described for Example by McPherson *et al* (1991). The particular nested PCR strategy of the invention involved the use of two amplification reactions in sequence, wherein the first amplification reaction used primers specific for pathogenic leptospire, for example the primers described by Hookey (1992) and more particularly the primers LU and rLP (Table 10) to amplify rRNA sequences from crude nucleic acid or tissue samples comprising same and the second amplification reaction further amplified the rDNA obtained from the first reaction using internal primers specific for the genus *Leptospira*. A positive control, consisting of tissue extract or crude nucleic acid sample seeded with  $10^5$  / ml serovar pomona organisms, was included in each amplification series.

The PCR reaction mixture consisted of 2.5 µl 10X Taq buffer containing 15mM MgCl<sub>2</sub>, 2.5 µl dNTP mixture comprising dATP, dCTP, dGTP and TTP (Promega), 0.5 µl of each primer at a concentration of 50 pmol/µl, 1 unit Taq DNA polymerase (Promega, diluted to 2 unit/µl), 8.5µl sterile distilled water and 10 µl sample. PCR reactions were performed in a Perkin-Elmer Gene Amp PCR System 2400. Amplification conditions were as follows: one cycle at 94°C for 3 min, 56°C for 1.5 min, 72°C for 2 min; twenty nine cycles at 94°C for 1 min, 56°C for 1.5 min, 72°C for 2 min; and one cycle at 94°C for 1 min, 56°C for 1.5 min, 72°C for 10 min.

The product of the first PCR reaction was diluted 1/10 in sterile distilled water, and 2.5 µl of diluted sample was included in a similar amplification reaction in a total volume of 25µl as before, using primers C and INT rLP (Table 10 ). Amplification conditions for the second reaction were similar to the initial round, however annealing reactions were at 61°C instead of 56°C.

**SUBSTITUTE SHEET (RULE 26)**

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:41PM

WO 98/40099

PCT/AU98/00145

- 57 -

The PCR products were subjected to electrophoresis on 1% (w/v) agarose gels containing ethidium bromide to detect a product of the predicted size. Amplified DNA was visualised by ultraviolet illumination after electrophoresis .

5

**EXAMPLE 11****PCR specific for serovar hurstbridge or serogroup Hurstbridge or *L. fainei***

Cultures of five isolated strains of the serovar hurstbridge/ serogroup Hurstbridge/ *L. fainei* isolates described in Table 3 and of seven pathogenic leptospiral species were grown in EMJH medium and adjusted to a concentration of  $2 \times 10^8$  organisms/ml. DNA was extracted by the silica absorption method of Boom *et al* (1990) and during this process a volume of 100  $\mu$ l of culture was reduced to 25  $\mu$ l, of which 5  $\mu$ l was tested in the PCR reaction. Thus, approximately  $4 \times 10^6$  organisms were tested in each PCR reaction.

A PCR was performed with oligonucleotide primers selected to detect specifically serovar hurstbridge or serogroup Hurstbridge rDNA sequences. The forward oligonucleotide primer (SEQ ID NO:2) corresponded to a region of the hurstbridge 16S ribosomal RNA gene which differed from that of other leptospires with which it was compared. The reverse oligonucleotide primer (SEQ ID NO:3) was as designed by Hookey (1992) and is one of a pair of primers used for a PCR test specific for pathogenic leptospires (Example 9).

The typical PCR reaction volume of 50  $\mu$ l consisted of 5  $\mu$ l sample, 5  $\mu$ l of buffer concentrate giving final concentrations of 0.1M Tris-HCl, pH 9.0, 0.5M KCl, 1% Triton X-100, 20mM  $MgCl_2$ , 5  $\mu$ l of dNTPs (each at a final concentration of 0.2 mM), 1  $\mu$ l forward primer and 1  $\mu$ l reverse primer at appropriate dilutions in water (each 50 pM), 5 units Taq DNA polymerase, and water to make up the volume.

PCR was performed in a Perkin Elmer Cetus GeneAmp PCR System 9600. The PCR conditions were as follows: a) one cycle of 94°C for 3 minutes, 63°C for 1.5 minutes, 72°C for 2 minutes; b) 29 cycles of 94°C for 1 minute, 63°C for 1.5 minutes, 72°C for 2 minutes; c) a further 10 minutes held at 72°C at the end of the reaction.

**SUBSTITUTE SHEET (RULE 26)**

WO 98/40099

PCT/AU98/00145

- 58 -

The PCR products were subjected to electrophoresis on 1% (w/v) agarose gels containing ethidium bromide to detect a product of the predicted size. Amplified DNA was visualised by ultraviolet illumination after electrophoresis. Results obtained are shown in Table 12.

5

TABLE 12

Results of PCR Specific for Serovar hurstbridge

Organism Tested	PCR Result
Serovar hurstbridge (5 strains)	Positive
10 <i>Leptospira interrogans</i> serovar pomona	Negative
<i>Leptospira borgpetersenii</i> serovar tarassovi	Negative
<i>Leptospira noguchi</i> serovar panama	Negative
<i>Leptospira kirschneri</i> serovar grippotyphosa	Negative
<i>Leptospira inadai</i> serovar lyme	Negative
15 <i>Leptospira weillii</i> serovar cellodoni	Negative
<i>Leptospira santarosai</i> serovar varela	Negative

This PCR reaction did not detect any serovar or serogroup other than serovar hurstbridge or serogroup Hurstbridge or *L. fainei*.

20

## EXAMPLE 12

## Passive vaccination of pigs

Fifteen piglets of approximately 4 weeks of age were acquired on 13 November 1997 and separated into three groups of five, each in an elevated pig pen in the same room. The three groups comprising 5 pigs each were administered with the following preparations:

- (Group A): 5 ml immune serum which was MAT positive for serovar hurstbridge (MAT titre 256) and derived from a pig that had been administered repeatedly with serovar hurstbridge;
- 30 (Group B): 5 ml non-immune pig serum which is MAT negative for serovar hurstbridge (serum control); and
- (Group C): no serum (untreated control).

SUBSTITUTE SHEET (RULE 25)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

093032T 920860

WO 98/40099

PCT/AU98/00145

- 59 -

Passive vaccination was performed on 24 November 1997 and piglets were subsequently challenged intraperitoneally with  $\geq 10^8$  serovar hurstbridge organisms on 25 November (Day 0). Blood and urine were collected at intervals between Day 1 and Day 10.

- 5 Evidence of infection by serovar hurstbridge was determined by testing serum for the presence of leptospiral DNA, as described in Example 10. Additionally, urine was examined under a dark ground microscope for the presence of leptospires. Attempts were made to culture leptospires from urine samples, by inoculating 3 drops of urine into 5 ml of EMJH medium and performing serial dilutions of 3 drops into 5 ml of medium therefrom
- 10 and finally, examining the cultures under a dark field microscope after approximately 1-2 weeks of culturing.

- Results are presented in Table 13. None of the five pigs vaccinated with immune serum (i.e. Group A) showed evidence of infection as determined using PCR and light microscopy of
- 15 cultured samples, however three out of five pigs in the control showed evidence of infection following challenge with serovar hurstbridge.

- To further characterise the passively immunised animals, serological data were obtained using MAT (Example 4) to determine whether leptospiral infection had occurred in piglets.
- 20 At 10 and 20 days post challenge, all ten control piglets (Groups B and C *supra*) had at least one titre to serovar hurstbridge in the range 32 to 512, indicating that these animals were infected (Table 14). In marked contrast, only one of the five passively-vaccinated piglets (Group A) developed a MAT titre of 32 or above (Table 14). Therefore, passive vaccination suppressed the serological evidence of infection.

25

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

WO 98/40099

PCT/AU98/00145

-60-

**TABLE 13**  
**Evidence of infection of passively-vaccinated piglets and control piglets.**

GROUP	TREATMENT	PIC	SERUM		URINE MICROSCOPY	URINE CULTURE	EVIDENCE OF INFECTION
			DAY 1	DAY 10			
A	Immune serum	R1	-	-	-	-	No
	Immune serum	R2	-	-	-	-	No
	Immune serum	R3	-	-	-	-	No
	Immune serum	R4	-	-	-	-	No
	Immune serum	R5	-	-	-	-	No
B	Negative serum	Y1	-	-	-	-	No
	Negative serum	Y2	-	-	+	-	Yes
	Negative serum	Y3	-	-	-	-	No
	Negative serum	Y4	-	-	+	-	Yes
	Negative serum	Y5	-	-	+	+	Yes

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

WO 98/40099

-61-

PCT/AU98/00145

GROUP	TREATMENT	PIG	SERUM		URINE		URINE CULTURE	EVIDENCE OF INFECTION
			PCR		MICROSCOPY	DAY 1		
			DAY 1	DAY 10			DAY 3	
C	No serum	P1	+	-	+	-		Yes
	No serum	P2	-	-	-	-		No
	No serum	P3	+	-	-	-		Yes
	No serum	P4	-	-	-	-		No
	No serum	P5	-	+	+	-		Yes

TABLE 13CONT.

5

10

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

WO 98/40099

PCT/AU98/00145

- 62 -

TABLE 14

**Serological evidence of infection of passively vaccinated  
piglets and control piglets**

MAT Titres of Serum for serovar hurstbridge						
Animal	Day 0	Day 1	Day 3	Day 6	Day 10	Day 20
<b>Group A:</b>						
R1	0	0	0	0	trace	trace
R2	0	0	0	trace	512	512
R3	0	0	0	0	0	0
R4	0	0	0	0	0	0
R5	0	0	0	0	0	0
<b>Group B:</b>						
Y1	0	0	0	32	256	64
Y2	0	0	0	0	128	64
Y3	0	0	0	32	128	512
Y4	0	0	0	0	32	0
Y5	0	0	0	0	128	128
<b>Group C:</b>						
P1	No sample	0	0	0	64	32
P2	0	0	0	trace	64	64
P3	0	0	0	0	64	0
P4	0	0	0	64	512	512
P5	0	0	0	0	256	256

**EXAMPLE 13**

**Protective immunisation of pigs using a heat-inactivated  
vaccine against serovar hurstbridge**

30

Twelve piglets of approximately 4 weeks of age were acquired on 13 November, 1997 and separated into two groups of six, each in a separate pen in the same room. Group A was vaccinated three times intramuscularly with an experimental vaccine containing at least 10<sup>8</sup> formalin-killed serovar hurstbridge organisms per dose, adjuvanted with aluminium hydroxide. Group B received a similarly prepared placebo vaccine, containing no

35

**SUBSTITUTE SHEET (RULE 26)**

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

WO 98/40099

PCT/AU98/00145

- 63 -

leptospiral organisms.

One pig in Group A died before challenge.

- 5 Pigs were subsequently challenged intraperitoneally with  $\geq 10^8$  serovar hurstbridge organisms on 5 January, 1998 (Day 0). Blood was collected at intervals between Day 0 and Day 10. Sera were tested by the MAT for serovar hurstbridge or serogroup Hurstbridge, as described in Example 4.
- 10 Table 15 shows the serological results of actively vaccinated and placebo treated piglets, from the day of challenge to the day of slaughter, 10 days after challenge. From these data, it can be seen that significant antibodies against serovar hurstbridge or serogroup Hurstbridge are present in Group A at challenge, whereas the control animals have no detectable antibodies against serovar hurstbridge or serogroup Hurstbridge at challenge.
- 15 Additionally, the serological response to challenge is more modest in the vaccinated group (i.e. Group A) than in the control group (i.e. Group B) which mostly possessed very high MAT titres by Day 10.
- 20 Table 16 shows the results of this experiment in terms of the increase in MAT titre in response to challenge. As shown in Table 16, the group A animals experienced a maximum 8-fold increase in MAT titre following challenge, compared to a maximum increase of 128-fold in the non-immunised animals. Given that the challenge dose of live organisms would be expected to induce a strong anamnestic response in animals to which it is administered, the data obtained for the Group A animals which had previously received three doses of
- 25 killed vaccine, are inconsistent with survival and proliferation of the hurstbridge in the vaccinated organisms *in vivo*. In contrast, four of the six Group B animals clearly exhibited signs of infection as determined by MAT.

These data demonstrates that vaccination of the piglets of Group A has inhibited the

30 survival and proliferation of serovar hurstbridge or serogroup Hurstbridge *in vivo*.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

WO 98/40099

PCT/AU98/00145

- 64 -

TABLE 15

5 Serum MAT titres for serovar hurstbridge following challenge of vaccinated and control piglets with serovar hurstbridge or serogroup Hurstbridge

MAT Titres of Serum for serovar hurstbridge					
Animal *	Day 0	Day 1	Day 2	Day 4	Day 10
<b>Group A:</b>					
10 <b>Pig 2</b>	128	512	512	512	512
<b>Pig 3</b>	64	128	128	128	128
<b>Pig 4</b>	256	1024	1024	1024	2048
<b>Pig 5</b>	128	128	128	128	512
<b>Pig 6</b>	128	256	256	512	256
<b>Group B:</b>					
15 <b>Pig 7</b>	0	0	0	0	0
<b>Pig 8</b>	0	0	0	32	2048
<b>Pig 9</b>	0	0	0	0	2048
<b>Pig 10</b>	0	0	0	0	trace
20 <b>Pig 11</b>	0	0	0	0	2048
<b>Pig 12</b>	0	0	0	0	512

\* Pig No. 1 died prior to challenge.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

WO 98/40099

PCT/AU98/00145

- 65 -

TABLE 16

**Increase in MAT titre in response to challenge with serovar hurstbridge or  
serogroup Hurstbridge in vaccinated and control piglets**

Animal *	Day of Challenge	At Slaughter	Increase in Titre*
<b>Group A:</b>			
Pig 2	128	512	4-fold
Pig 3	64	128	2-fold
Pig 4	256	2048	8-fold
Pig 5	126	512	4-fold
Pig 6	128	256	2-fold
<b>Group B:</b>			
Pig 7	0	0	0
Pig 8	0	2048	128-fold
Pig 9	0	2048	128-fold
Pig 10	0	trace	0
Pig 11	0	2048	128-fold
Pig 12	0	512	32-fold

\* Pig No. 1 died prior to challenge.

## EXAMPLE 14

**Production of a rabbit antiserum against serovar hurstbridge  
or serogroup Hurstbridge  
isolated from Herd B**

Isolate 1 (Table 3) was grown in culture to about  $10^8$  organisms/ml in Korthof's (protein-free) medium. The culture was heated at  $56^\circ\text{C}$  for 30 minutes to kill the leptospire and emulsified with an equal volume of Montanide ISA 50 adjuvant. A rabbit was immunised weekly for six weeks with 2ml of adjuvanted leptospire, each dose being distributed over ten subcutaneous sites. Blood was obtained from the ear two weeks after the last dose.

WO 98/40099

PCT/AU98/00145

- 66 -

**EQUIVALENTS**

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.

**10 REFERENCES**

1. Ausubel *et al.*, (1987). *In: Current Protocols in Molecular Biology*. Wiley Interscience (ISBN 47150338).
2. Boom, R., Sol C.J.A.; Salimans, M. M. M.; Jansen, C.L.; Wertheim-van Dillen, P.M.E. and van der Noordaa, J. (1990). *J. Clin. Microbiol.* **28**, 495-503.
- 15 3. Chappel, R.J. (1993b) Leptospirosis. Pathology, Bacteriology and Serology. Australian Standard Diagnostic Techniques for Animal Diseases. *In: Standing Committee on Agriculture and Resource Management*.
4. Chappel, R.J., Adler, B., Jones, R.T., Mead, L., Millar, R.W. and Skilbeck, N.W. (1987a) *Proc. Aust. Pig Sci. Assoc.* **1**, 232.
- 20 5. Chappel, R.J., Adler, B., Jones, R.T. and Millar, B.D. (1990) Leptospirosis. *In: Aust. Pig Manual Volume 33*. (eds. J. Gardiner and A.C. Dunkin) Pig Research Council. In press.
6. Chappel, R.J., Adler, B., Millar, B.D. and Jones, R.T. (1987b) Porcine Leptospirosis. *In: Proc. Postgraduate Committee in Vet. Sci., University of Sydney "Pig Production"*. pp 1112-1118.
- 25 7. Chappel, R.J., Billingham, M.L., Wan, S.S., Hennessy, D.P., Ellis, W.A. and Adler, B. (1993a) *Manipulating Pig Production* **4**, 253.
8. Chappel, R.J., Ellis, W.A., Adler, B., Amon, L., Millar, B.D., Zhu, S.S. and Prime, R.W. (1992) *Aust. Vet. J.* **69**, 119-120.
- 30 9. Cole, J.R., Sulzer, C.R. and Pursell, A.R. (1973) *Appl. Microbiol.* **25**, 976-980.
10. Cole *et al.* (1985) *In: Monoclonal antibodies in cancer therapy*, Alan R. Bliss Inc.,

**SUBSTITUTE SHEET (RULE 26)**

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

WO 98/40099

PCT/AU98/00145

- 67 -

pp 77-96.

11. Davos, D. (1977) *Aust. Vet. J.* **53**, 151-152.
12. Ellis, W.A., McParland, P.J., Bryson, D.J. and Cassells, J.S. (1986a) *Vet. Rec.* **118**, 563.
- 5 13. Ellis, W.A., McParland, P.J., Bryson, D.J. and McNulty, M.S. (1985) *Vet. Rec.* **117**, 66-67.
14. Ellis, W.A., McParland, P.J., Bryson, D.J., Thiermann, A.B. and Montgomery, J. (1986b) *Vet. Rec.* **118**, 294-295.
- 10 15. Ellis, W.A., O'Brien, J.J., Cassells, J.S. and Montgomery, J. (1983) *Equine Vet. J.* **15**, 317-320.
16. Faine, S. (1994) *In: Leptospira and Leptospirosis*. CRC Press, Boca Raton. ppl.
17. Frantz, J.C., Hanson, L.E. and Brown, A.L. (1988) *Proc. Am. Assoc. Swine Pract.* **972**, 102.
- 15 18. Hookey, J.V. (1992) *FEMS Microbiol. Lett.* **90**, 267-274.
19. Huse *et al.* (1989) *Science* **246**, 1275-1281;
20. Kohler and Milstein (1975) *Nature* **256**, 495-499;
21. Kozbor *et al.* (1983) *Immunol. Today* **4**, 72.
22. Lane, D. J. (1991) *In: Nucleic acid techniques in bacterial systematics*. (eds. E. Stackebrandt and M. Goodfellow) John Wiley & Sons Ltd., Chichester.
- 20 23. McPherson, M.J., Quirke, P. and Taylor, G.R. (1991) *In: PCR A Practical Approach*. IRL Press at Oxford University Press, Oxford. (ISBN 019963226).
24. Merien, F., Amouriaux, P., Perolat, P., Baranton, G., and Saint-Girons, I. (1992). *J. Clin. Microbiol.* **30**, 2219.
- 25 25. Perolat, P., Chappel, R.J., Adler, B., Baranton, G., Bulach, D.M., Billinghamurst, M.L., Letocart, M., Merien, F. and Serrano, M.S. (1998) *Int. J. Syst. Bacteriol.* Description, characterisation and phylogenetic analysis of *Leptospira fainei* sp. nov., isolated from pigs in Australia. Manuscript in press.

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

66227 9280860

WO 98/40099

PCT/AU98/00145

- 68 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

(i) APPLICANT: Agriculture Victoria Services Pty Ltd  
AND Pig Research and Development Corporation

(ii) TITLE OF INVENTION: NOVEL BACTERIAL PATHOGENS

10

(iii) NUMBER OF SEQUENCES: 26

(iv) CORRESPONDENCE ADDRESS:

15

(A) ADDRESSEE: DAVIES COLLISON CAVE  
(B) STREET: 1 LITTLE COLLINS STREET  
(C) CITY: MELBOURNE  
(D) STATE: VICTORIA  
(E) COUNTRY: AUSTRALIA  
(F) ZIP: 3000

20

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT INTERNATIONAL  
(B) FILING DATE: 06-MAR-98

30

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: P05494/97  
(B) FILING DATE: 07-MAR-97

35

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: HUGHES E. JOHN L.

(ix) TELECOMMUNICATION INFORMATION:

40

(A) TELEPHONE: +61 3 9254 2777  
(B) TELEFAX: +61 3 9254 2770  
(C) TELEX: AA 31787

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:40PM

66221 " 0000000000

WO 98/40099

PCT/AU98/00145

- 69 -

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1477 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## 10 (ii) MOLECULE TYPE: DNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

60 GATCATGGCT CAGAACTAAC GCTGGCGGCG CGTCTTAAC ATGCAAGTCG AGCGGGGTAG 60  
15 CAATACCTAG CGGCGAACGG GTGAGTAACA CGTGSTAATC TTCCTCCGAG TCTGGGATAA 120  
CTTCCGAAA GGAAAGCTAA TACCGGATAG TCCTGTTGGA TCACAAGATT TGATAGGTAA 180  
20 AGATTTATTG CTTGGAGATG AGCCCGCGGC CGATTAGCTA GTTGGTGAGG TAATGGGTCA 240  
CCAAGGCGAC GATCGGTAGC CGGCCTGAGA GGGTGTCCGG CCACAATGGA ACTGAGACAC 300  
GGTCCATACT CCTACGGGAG GCAGCAGTTA AGAATCTTGC TCAATGGGGG AAACCCTGAA 360  
25 GCAGCGACGC CGCGTGAACG AAGAAGGTCT TCGGATTGTA AAGTTCATTA GGCAGGAAAA 420  
ATAAGCAGCA ATGTGATGAT GGTACCTGCC TAAAGCACCG GCTAACTACG TGCCAGCAGC 480  
30 CGCGGTAATA CGTATGGTGC AAGCGTTGTT CGGAATCATT GGGCGTAAAG GGTGCGTAGG 540  
CGGATTGTA AGTCAGGTGT GAAAAGTCCG GGCTCAACCC GTGGCCTGCA CTTGAAACTA 600  
CAAGTCTGGA GTTTGGGAGA GGCAAGTGGA ATTCAGGTG TAGCGGTGAA ATGCGTAGAT 660  
35 ATCTGGAGGA ACACCAAGTGG CGAAGGCGAC TTGCTGGCTC AAAACTCAGC CTGAGGCACG 720  
AAAGCGTGGG TAGTAAACGG GATTAGATAC CCCGGTAATC CACGCCCTAA ACGTTGTCTA 780  
40 CCAGTTGTTG GGGGTTTTAA CCCTCAGTAA CGAACCTAAC GGATTAAGTA GACCGCCTGG 840

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

WO 98/40099

PCT/AU98/00145

- 70 -

GGACTATGCT CGCAAGAGTG AAACTCAAAG GAATTGACGG GGGTCCGCAC AAGCGGTGGA 900

GCATGTCGTT TAATTCGATG ATACCCCAAA AACCTCACCT GGGCTTGACA TGGATCTGAA 960

5 TCATGTAGAG ATATATGAGC CTTCCGGGCAG ATTCACAGGT GCTGCATGGT TGTCGTCAGC 1020

TCGTGTCGTG AGATGTTGGG TTAAGTCCCG CAACGAGCGC AACCCCTATC GTATGTTGCT 1080

ACCTTAAGTT GGGCACTGGT ACGAACTGC CGGTGACAAA CCGGAGGAAG GCGGGGATGA 1140

10 CGTCAAATCC TCATGGCCTT TATGTCCAGG GCCACACAG TGCTACAATG GCCGATACAG 1200

AGGGTCGCCA ACTCGCAAGA GGGAGCTAAT CTCTAAAAGT CGGTCCCACT TCGGATTGGG 1260

15 GTCTGCAACT CCACCCCATG AAGTCGSAAT CGCTAGTAAT CGCGGATCAG CATGCCGCGG 1320

TGAATACGTT CCCGGACCTT GTACACACCG CCCGTCACAC CACCTGAGTG GGGAGCACCC 1380

GAAGTGGTCT TTGTTAACCG TAAGGAGACA GACTACTAAG GTGAAACTCG TAAAGGGGGT 1440

20 GAAGTCGTAA CAAGGTACCG TAAATCGATT CCTGCAG 1477

25 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

30 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TGTTGGATCA CAAGATTGTA TA

22

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

WO 98/40099

PCT/AU98/00145

- 71 -

## (2) INFORMATION FOR SEQ ID NO:3:

## (1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTCACCGCTA CACCTGGAA

19

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TGTTGGA

7

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

WO 98/40099

PCT/AU98/00145

- 72 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTTGATA

7

5

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: DNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TGTTGGANNN NNNNNTTTGA TA

22

20

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TGTTGGATCA CAAGATTGA TA

22

35

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 200 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single

40

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

662227 " 92808650

WO 98/40099

PCT/AU98/00145

- 73 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CCGAGTCTGG GATAACTTTC CGAAAGGAAA GCTAATACCG GATAGTCCTA CTGGATCACA 60  
GGATCTGATA GGTAAAGATT TATTGCTTGG AGATGAGCCC GCGGCCGATT AGCTAGTTGG 120  
TGAGGTAAAG GCTCACCAAG GCGACGATCG GTAGCCGGCC TGAGAGGGTG TCCGGCCACA 180  
ATGGAAGTGA GACACGGTCC 200

15

(2) INFORMATION FOR SEQ ID NO:9.

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 200 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: DNA

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CCGAGTCTGG GATAACTTTT CGAAAGGGAA GCTAATACTG GATAGTCCCG AGAGATCATA 60  
AGATTTTTCG GGTAAAGATT CATTGCTTGG AGATGAGCCC GCGTCCGATT AGCTAGTTGG 120  
TGAGGTAATG GCTCACCAAG GCGACGATCG GTAGCCGGCC TGAGAGGGTG TCCGGCCACA 180  
ATGGAAGTGA GACACGGTCC 200

35

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 200 base pairs  
(B) TYPE: nucleic acid

40

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

662217 " 92303E60

WO 98/40099

PCT/AU98/00145

- 74 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CCGAGTCTGG GATAACTTTC CGAAAGGGGA GCTAATACTG GATGGTCCCG AGAGGTCATA 60

10 TGATTTTTCG GGTAAAGATT TATTGCTCGG AGCTGAGCCC GCGCCCGATT AGCTAGTTGG 120

TGAGGTAATG GCTCACCAAG GCGACGATCG GTAGCCGGCC TGAGAGGGTG TTCGGCCACA 180

ATGGAACTGA GACACGGTCC 200

15

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

20

(A) LENGTH: 200 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CCGAGTCTGG GATAACTTTC CGAAAGGGGA GCTAATACTG GATAGTCCCG ATAGATCATA 60

30

GGATGTATCG GGTAAAGATT CATTGCTCGG AGATGAGCCC GCGCCCGATT AGCTAGTTGG 120

TGAGGTAAAG GCTCACCAAG GCGACGATCG GTAACCGGCC TGAGAGGGTG TTCGGCCACA 180

35

ATGGAACTGA GACACGGTCC 200

(2) INFORMATION FOR SEQ ID NO:12:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 200 base pairs

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

66222T"92308860

WO 98/40099

PCT/AU98/00145

- 75 -

- (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

10 CCGAGTCTGG GATAACTTTC CGAAAGGGGA GCTAATACTG GATAGTCCCG AGAGGTCATA 60  
GGATTTTTCG GGTAAAGATT TATTGCTCGG AGATGAGCCC GCGCCCGATT AGCTAGTTGG 120  
TGAGGTAATG GCTCACCAAG GCGACGATCG GTAGCCGGCC TGAGAGGGTG TTCGGCCACA 180  
15 ATGGAAGTGA GACACGGTCC 200

(2) INFORMATION FOR SEQ ID NO:13:

20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 200 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

30 CCGAGTCTGG GATAACTTTC CGAAAGGGAA GCTAATACTG GATAGTCCCG AGAGATCATA 60  
AGATTTTTCG GGTAAAGATT CATGCTCGG AGATGAGCCC GCGTCCGATT AGCTAGTTGG 120  
TGAGGTAATG GCTCACCAAG GCGACGATCG GTAGCCGGCC TGAGAGGGTG TTCGGCCACA 180  
35 ATGGAAGTGA GACACGGTCC 200

(2) INFORMATION FOR SEQ ID NO:14:

40 (i) SEQUENCE CHARACTERISTICS:

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

WO 98/40099

PCT/AU98/00145

- 76 -

- (A) LENGTH: 199 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

10

CCGAGTCTGG GATAACTTTC CGAAAGGGAA GCTAATACTG GATGGTCCCG AGAGATCATA 60

AGATTTTTCG GGTAAAGATT TATTGCTCGG AGATGAGCCC GCGTCCGATT AGCTAGTTGG 120

15

TGAGGTAAAG GCTCACCAAG GCGACGATCG GTAGCCGGCC TGAGAGGGTG TTCGGCCACA 180

ATGGAACTGA GACACGGTCC 200

20

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 200 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CTGAGTCTGG GATAACTTTC CGAAAGGGAA GCTAATACTG GATGGTCCCG AGAGATCATA 60

AGATTTTTCG GGTAAAGATT TATTGCTCGG AGATGAGCCC GCGTCCGATT AGCTAGTTGG 120

35

TGAGGTAAAG GCTCACCAAG GCGACGATCG GTAGCCGGCC TGAGAGGGTG TTCGGCCACA 180

ATGGAACTGA GACACGGTCC 200

40

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

WO 98/40099

PCT/AU98/00145

- 77 -

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS.

(A) LENGTH. 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CATGGATCCA GAGTTTGATC MTGGCTCAG

29

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GTGCCAGCMG CCGCGG.

16

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

WO 98/40099

PCT/AU98/00145

- 78 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

AAACTYAAAK GAATTGACGG

20

5

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

10

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CGGCGCGTCT TAAACATG

18

20

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CAAGTCAAGC GGAGTAGCAA

20

35

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 base pairs

40

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

WO 98/40099

PCT/AU98/00145

- 79 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ACGGGCGGTG TGTRC

15

10 (2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 base pairs

(B) TYPE: nucleic acid

15 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GGGTTGCGCT CGTTG

15

(2) INFORMATION FOR SEQ ID NO:23:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

35

GWATTACCGC GGCKGCTG

18

(2) INFORMATION FOR SEQ ID NO:24:

40

(i) SEQUENCE CHARACTERISTICS:

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:39PM

WO 98/40099

PCT/AU98/00145

- 80 -

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

10 ACCATCATCA CATYGCTGC

19

(2) INFORMATION FOR SEQ ID NO:25:

15

(i) SEQUENCE CHARACTERISTICS.

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

25 TTCCTCCCAT TGAGCAAGAT T

21

(2) INFORMATION FOR SEQ ID NO:26:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

40 TTATTTTTCG CTGCTTACTG AAC

23

SUBSTITUTE SHEET (RULE 26)

RECEIVED TIME SEP. 2. 9:55PM

PRINT TIME SEP. 2. 10:38PM

**CLAIMS:**

1. An isolated pathogenic *Leptospira* bacterium which belongs to serogroup Hurstbridge or serovar hurstbridge as hereinbefore defined or a derivative bacterium thereof which is serologically cross-reactive to a bacterium belonging to serogroup Hurstbridge or serovar hurstbridge.
2. The isolated pathogenic *Leptospira* bacterium according to claim 1, wherein said bacterium exhibits the growth characteristics of *Leptospira* strain WKID (AGAL Accession No. N95/69684) or *Leptospira* strain BUT6.
3. The isolated pathogenic *Leptospira* bacterium according to claim 2, wherein said bacterium is capable of growing in media containing at least 100µg/ml 8-azaguanine.
4. The isolated pathogenic *Leptospira* bacterium according to claims 2 or 3, wherein said bacterium is capable of growing at temperatures in the range from about 13°C to about 37°C.
5. The isolated pathogenic *Leptospira* bacterium according to any one of claims 1 to 4, wherein said bacterium is a pathogen which is capable of infecting a human or a livestock animal or a companion animal selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.
6. The isolated pathogenic *Leptospira* bacterium according to claim 5, wherein said bacterium is capable of infecting pigs.
7. The isolated pathogenic *Leptospira* bacterium according to claim 5, wherein said bacterium is capable of infecting humans.
8. The isolated pathogenic *Leptospira* bacterium according to claim 5, wherein said

bacterium is capable of infecting bovines.

9. The isolated pathogenic *Leptospira* bacterium according to any one of claims 5 to 8, wherein said bacterium is capable of producing the symptoms of leptospirosis in a human or other animal which it infects.

10. The isolated pathogenic *Leptospira* bacterium according to any one of claims 1 to 8, wherein said bacterium is capable of inducing reproductive disease.

11. The isolated pathogenic *Leptospira* bacterium according to claim 10, wherein the reproductive disease induced by said bacterium comprises reduced farrowing.

12. The isolated pathogenic *Leptospira* bacterium according to claim 10, wherein the reproductive disease induced by said bacterium comprises foetal death *in utero* or spontaneous abortion.

13. The isolated pathogenic *Leptospira* bacterium according to claim 10, wherein the reproductive disease induced by said bacterium produces an increased weaning-to-mating period in the offspring of an infected animal.

14. The isolated pathogenic *Leptospira* bacterium according to claim 10, wherein the reproductive disease induced by said bacterium comprises seasonal infertility.

15. The isolated *Leptospira* bacterium according to any one of claims 1 to 14, wherein said bacterium further contains nucleic acid which is at least about 80% identical to the nucleotide sequence set forth in any one of SEQ ID NOs:1-2 or 4-7 or a homologue, analogue or derivative thereof comprising at least 15 contiguous nucleotides which are at least about 80% identical to the nucleotide sequence set forth in said SEQ ID NOs. or a complementary nucleotide sequence thereto.

16. The isolated *Leptospira* bacterium according to any one of claims 1 to 14 wherein said bacterium further comprises a rRNA gene sequence which is at least 80% identical to the nucleotide sequence 5'-TGTTGGA-3' or at least 90% identical to the nucleotide sequence 5'-TTTGATA-3' or a homologue, analogue or derivative thereof or a complementary nucleotide sequence thereto.

17. The isolated *Leptospira* bacterium according to claim 16 wherein the rRNA gene sequence comprises a nucleotide sequence which is at least 85% identical to the nucleotide sequence 5'-TGTTGGATCACAAGATTTGATA or a homologue, analogue or derivative thereof or a complementary nucleotide sequence thereto.

18. The isolated *Leptospira* bacterium according to any one of claims 15 to 17 wherein the percentage identity is at least about 97%.

19. The isolated pathogenic *Leptospira* bacterium according to any one of claims 1 to 18 having the characteristics of the microorganism deposited under AGAL Accession No. N95/69684 or which is serologically cross-reactive thereto.

20. An isolated *Leptospira* bacterium deposited under AGAL Accession No. N95/69684.

21. A method of isolating the *Leptospira* bacterium according to any one of claims 1 to 20, said method comprising the steps of:

- (i) collecting tissue from a human or other animal subject infected therewith;
- (ii) homogenising said tissue in a suitable homogenisation medium for a time and under conditions sufficient to release said bacterium from said tissue whilst maintaining the integrity of said bacterium; and
- (iii) culturing the homogenised tissue in a suitable culture medium for a time and under conditions sufficient to allow said bacterium to grow.

- 84 -

22. The method according to claim 21, wherein the culture medium is EMJH medium.
23. The method according to claim 21 or 22, wherein the culture medium is supplemented with 8-azaguanine or 5-fluorouracil.
24. The method according to any one of claims 21 to 23, wherein the culture medium is supplemented with at least one antibiotic.
25. The method according to claim 24, wherein the antibiotic is selected from the list comprising rifamycin, macrolide polyene and quinoline or a derivative compound thereof.
26. The method according to any one of claims 21 to 25, wherein the culture conditions comprise growth in the temperature range from about 13°C to about 37°C.
27. The method according to any one of claims 21 to 26 wherein the other animal subject is a livestock animal or a companion animal.
28. The method according to claim 27, wherein the livestock animal or companion animal is selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.
29. The method according to claim 28, wherein the livestock animal is a pig.
30. The method according to any one of claims 21 to 29, wherein the tissue is blood, serum, plasma, urine, cerebrospinal fluid, liver, lung or tissue derived from the urogenital tract selected from the list comprising bladder, kidney, uterus or fallopian tube or testes.
31. The method according to claim 30, wherein the tissue is kidney or urine.
32. An antibody molecule which is capable of binding to the isolated *Leptospira*

- 85 -

bacterium according to any one of claims 1 to 20 or an antigen derived from said bacterium.

33. The antibody molecule according to claim 32, further defined as a polyclonal antibody molecule.

34. A method of diagnosing the presence of the pathogenic *Leptospira* bacterium according to any one of claims 1 to 20 in a biological sample derived from a human or other animal subject, said method comprising contacting said biological sample or a nucleic acid molecule derived therefrom with one or more isolated probes or primers comprising a nucleotide sequence set forth in any one of SEQ ID Nos:2-7 or a homologue, analogue or derivative thereof or a complementary sequence thereto for a time and under conditions sufficient for hybridisation to occur and then detecting said hybridisation using a detecting means.

35. The method according to claim 34, wherein the detecting means is a reporter molecule which is bound to the isolated nucleic acid molecule probe.

36. The method according to claim 35, wherein the reporter molecule is a radioisotope or biotin.

37. The method according to claim 34, wherein the detecting means is a polymerase chain reaction.

38. The method according to claim 37, wherein the polymerase chain reaction employs at least one primer comprising a nucleotide sequence set forth in SEQ ID NO:2 or SEQ ID NO:3 or a derivative thereof.

39. The method according to claim 37, wherein the polymerase chain reaction employs two primers comprising the nucleotide sequences set forth in SEQ ID NOS:2 and 3 or a derivative of any one of said nucleotide sequences.

40. The method according to any one of claims 37 to 39 comprising a nested PCR wherein:

- (i) the first amplified gene sequence obtained from a first round of amplification is contacted with one or more second nucleic acid primers of at least about 15 nucleotides in length derived from the nucleotide sequence set forth in SEQ ID NO:1 or a complementary sequence thereto capable of hybridising at a position in said first amplified gene sequence which is internal to the position of the nucleic acid primer sequence(s) used to generate said first amplified gene sequence; and
- (ii) copies of said first amplified gene sequence are amplified using PCR to produce a second amplified product comprising *Leptospira* serovar hurstbridge or serogroup Hurstbridge rRNA gene sequences.

41. The method according to any one of claims 37 to 40, comprising the further step of sequencing the amplified nucleic acid molecule product.

42. A method of diagnosing the presence of the pathogenic *Leptospira* bacterium according to any one of claims 1 to 20 in a biological sample derived from a human or other animal subject, said method comprising contacting said biological sample with an antibody molecule that binds to said bacterium or an antigen thereof for a time and under conditions sufficient for an antibody:antigen complex to occur and then detecting said complex using a detecting means.

43. A method of diagnosing a past or present infection of a human or other animal subject by the pathogenic *Leptospira* bacterium according to any one of claims 1 to 20, said method comprising contacting a biological sample such as blood, serum, or a derivative thereof derived from said human or animal subject with said pathogenic *Leptospira* bacterium or an antigen derived therefrom for a time and under conditions sufficient for an antibody:antigen complex to occur and then detecting said complex using a detecting means.

- 87 -

44. The method according to claims 42 or 43 comprising an immunoassay or serological assay.
45. The method according to claim 44, wherein the immunoassay or serological assay comprises MAT or ELISA.
46. A method of diagnosing the presence of the pathogenic *Leptospira* bacterium according to any one of claims 1 to 20 in a human or other animal subject, said method at least comprising the steps of culturing cells or tissue derived from said subject under selective culture conditions which are specific for said bacterium for a time and under conditions sufficient to allow said bacterium to grow.
47. The method according to claim 46, wherein the selective culture conditions comprise growth at a temperature in the range from about 13°C to about 37°C on a culture medium supplemented with 8-azaguanine or 5-fluorouracil.
48. The method according to claim 47, wherein the culture medium is supplemented with at least one antibiotic.
49. The method according to claim 48, wherein the antibiotic is selected from the list comprising rifamycin, macrolide polyene and quinoline or a derivative compound thereof.
50. The method according to any one of claims 34 to 49, wherein the other animal subject is a livestock animal or a companion animal.
51. The method according to claim 50, wherein the livestock animal or companion animal is selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.
52. The method according to claim 51, wherein the livestock animal is a pig.

- 88 -

53. The method according to claim 51, wherein the livestock animal is a bovine animal.

54. The method according to any one of claims 34 to 53, wherein the biological sample comprises a homogenate or tissue or cell extract or whole cells or tissues derived from serum, blood, urine, cerebrospinal fluid, liver, lung, bladder, kidney, uterus, fallopian tube or testes.

55. The method according to claim 54, wherein the tissue is the biological sample comprises a homogenate or tissue or cell extract or whole cells or tissues derived from serum, blood, urine or kidney.

56. A diagnostic kit for the detection of the pathogenic *Leptospira* bacterium according to any one of claims 1 to 20 in a human or other animal subject or a biological sample derived therefrom, said kit at least comprising a first compartment which contains one or more immunogens derived from said pathogenic *Leptospira* bacterium and a second compartment which contains an antibody molecule that binds to said bacterium or an antigen thereof.

57. A diagnostic kit for the detection of the pathogenic *Leptospira* bacterium according to any one of claims 1 to 20 in a human or other animal subject or a biological sample derived therefrom, said kit at least comprising a first compartment which contains two non-complementary nucleic acid primer molecules of at least about 15 nucleotides in length comprising a nucleotide sequence set forth in any one of SEQ ID NOS:2-7 and a second compartment which contains a reaction buffer suitable for the performance of a nucleic acid hybridisation reaction or polymerase chain reaction.

58. A composition which is capable of conferring protective immunity against the pathogenic *Leptospira* bacterium according to any one of claims 1 to 20 in a human or animal subject, said composition comprising an attenuated form of said pathogenic *Leptospira* bacterium or one or more isolated or recombinant immunogens which are

- 89 -

immunologically cross-reactive with a cellular component thereof and one or more pharmaceutically or veterinarily acceptable carriers, adjuvants and/or diluents.

59. The composition according to claim 58, wherein the attenuated form of the pathogenic *Leptospira* bacterium is a killed bacterium or a killed bacterial culture.

60. The composition according to claim 58 or claim 59, wherein the pathogenic *Leptospira* bacterium is present at a concentration of at least about  $10^8$  organisms per unit dose.

61. The composition according to claim 58, wherein the adjuvant comprises aluminium hydroxide.

62. A composition which is capable of conferring protective immunity against the pathogenic *Leptospira* bacterium according to any one of claims 1 to 20 in a human or animal subject, said composition comprising serum derived from a human or other animal which is infected with said pathogenic *Leptospira* bacterium or a derivative product of said serum and one or more pharmaceutically or veterinarily acceptable carriers, adjuvants and/or diluents, wherein said serum or derivative comprises antibodies which are capable of binding to the pathogenic *Leptospira* bacterium or to one or more immunogens thereof.

63. The composition according to claim 62 wherein the serum or a derivative product thereof is capable of producing a MAT titre of at least about 256.

64. A method of prophylactic or therapeutic treatment of infection of a human or animal subject by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or a serologically cross-reactive derivative thereof, said method comprising administration of the composition according to any one of claims 58 to 63 to said human or animal subject for a time and under conditions sufficient to induce an immune response in said subject.

- 90 -

65. The method according to claim 64 wherein the immune response is a humoral immune response.

66. A method of prophylactic or therapeutic treatment of leptospirosis in a human or animal subject comprising administration of the composition according to any one of claims 58 to 63 to said subject for a time and under conditions sufficient for said subject to resist a subsequent challenge by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or a serologically cross-reactive derivative thereof.

67. A method of prophylactic or therapeutic treatment of reproductive disease in a human or animal subject comprising administration of the composition according to any one of claims 58 to 63 to said subject for a time and under conditions sufficient for said subject to resist a challenge by a pathogenic *Leptospira* bacterium of serogroup Hurstbridge or serovar hurstbridge or a serologically cross-reactive derivative thereof.

68. The method according to claim 67, wherein the reproductive disease is associated with seasonal infertility, reduced farrowing, foetal death *in utero* or spontaneous abortion in the infected subject or with increased weaning-to-mating period in the offspring of the infected subject.

69. The method according to any one of claims 64 to 68, wherein the composition is administered by injection.

70. The method according to any one of claims 64 to 69 wherein the subject being treated is a human.

71. The method according to any one of claims 64 to 69, wherein the subject being treated is a livestock animal or a companion animal.

72. The method according to claim 71 wherein the livestock animal or companion

- 91 -

animal is selected from the list comprising pigs, bovines, sheep, goats, horses, deer, alpaca, dogs and cats.

73. The method according to claim 72, wherein the livestock animal is a pig.

74. The method according to claim 72 wherein the livestock animal or companion animal is a bovine animal.

09/380826

1/3




FIGURE 1

660227-660226

09/380826

2/3

[illegible]

	1	50
HURSTBRIDGE	CCGAG	TCTGG
LYME	GATAA	CTTTC
RANARUM	CCGAG	TCTGG
CELLEDONI	GATAA	CTTTC
SHERMANI	CCGAG	TCTGG
JAVANICA	GATAA	CTTTC
PANAMA	CCGAG	TCTGG
CYNOPTERI	GATAA	CTTTC
ICTERO-	CCGAG	TCTGG
HAEMORRHAGIAE	GATAA	CTTTC

[illegible]

FIGURE 2 (CONT. I)

[illegible]

	101								150	
HURSTBRIDGE	GCGGC	CGATT	AGCTA	GTTGG	TGAGG	TAAATG	GCTCA	CCAAG	GCGAC	GATCG
LYME	GCGGC	CGATT	AGCTA	GTTGG	TGAGG	TAAAG	GCTCA	CCAAG	GCGAC	GATCG
RANARUM	GCGTC	CGATT	AGCTA	GTTGG	TGAGG	TAAATG	GCTCA	CCAAG	GCGAC	GATCG
CELLEDONI	GCGCC	CGATT	AGCTA	GTTGG	TGAGG	TAAATG	GCTCA	CCAAG	GCGAC	GATCG
SHERMANI	GCGCC	CGATT	AGCTA	GTTGG	TGAGG	TAAAG	GCTCA	CCAAG	GCGAC	GATCG
JAVANICA	GCGCC	CGATT	AGCTA	GTTGG	TGAGG	TAAATG	GCTCA	CCAAG	GCGAC	GATCG
PANAMA	GCGTC	CGATT	AGCTA	GTTGG	TGAGG	TAAATG	GCTCA	CCAAG	GCGAC	GATCG
CYNOPTERI	GCGTC	CGATT	ASCTA	GTTGG	TGAGG	TAAAG	GCTCA	CCAAG	GCGAC	GATCG
ICTERO -	GCGTC	CGATT	AGCTA	GTTGG	TGAGG	TAAAG	GCTCA	CCAAG	GCGAC	GATCG
HAEMORRHAGIAE	*					*				

	151									200
HURSTBRIDGE	GTAGC	CGGCC	TGAGA	GGGTG	TCCGG	CCACA	ATGGA	ACTGA	GACAC	GGTCC
LYME	GTAGC	CGGCC	TGAGA	GGGTG	TCCGG	CCACA	ATGGA	ACTGA	GACAC	GGTCC
RANARUM	GTAGC	CGGCC	TGAGA	GGGTG	TCCGG	CCACA	ATGGA	ACTGA	GACAC	GGTCC
CELLEDONI	GTAGC	CGGCC	TGAGA	GGGTG	TCCGG	CCACA	ATGGA	ACTGA	GACAC	GGTCC
SHERMANI	GTAAC	CGGCC	TGAGA	GGGTG	TCCGG	CCACA	ATGGA	ACTGA	GACAC	GGTCC
JAVANICA	GTAGC	CGGCC	TGAGA	GGGTG	TCCGG	CCACA	ATGGA	ACTGA	GACAC	GGTCC
PANAMA	GTAGC	CGGCC	TGAGA	GGGTG	TCCGG	CCACA	ATGGA	ACTGA	GACAC	GGTCC
CYNOPTERI	GTAGC	CGGCC	TGAGA	GGGTG	TCCGG	CCACA	ATGGA	ACTGA	GACAC	GGTCC
ICTERO -	GTAGC	CGGCC	TGAGA	GGGTG	TCCGG	CCACA	ATGGA	ACTGA	GACAC	GGTCC
HAEMORRHAGIAE	*				*					

FIGURE 2 (CONT. II)

Page 1

Attorney's Docket No. \_\_\_\_\_

## DECLARATION AND POWER OF ATTORNEY - USA PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "Leptospira pathogenus"

the specification of which:

- (a) ☐ is attached hereto; or
- (b) ☐ was filed on \_\_\_\_\_ as ☐ Application No. 0 / \_\_\_\_\_ or ☐ Express Mail No., as Application No. not yet known \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable); or
- (c) ☒ was described and claimed in PCT International Application No. PCT/AU98/00145 filed on 6 March 1998 and as amended under PCT Article 19 on \_\_\_\_\_ (if any) and/or under PCT Article 34 on \_\_\_\_\_ (if any).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56;

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent, design or inventor's certificate or any PCT international application(s) listed below and have also identified below any foreign application(s) for patent, design or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed for the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 U.S.C. § 119	
Australia	PO 5494	7 March 1997	<input checked="" type="checkbox"/> YES	NO <input type="checkbox"/>
			<input type="checkbox"/> YES	NO <input type="checkbox"/>
			<input type="checkbox"/> YES	NO <input type="checkbox"/>
			<input type="checkbox"/> YES	NO <input type="checkbox"/>
			<input type="checkbox"/> YES	NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below, and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56, which became available between the filing date of the prior application and the national or PCT international filing date of this application:

KNOBBE, MARTENS, OLSON & BEAR, LLP  
670 HILLCREST CENTER DR. 10TH FLOOR NEWPORT BEACH, CA 92660  
(714) 742-0000 FAX (714) 742-0002

RECEIVED TIME NOV. 9. 8:05PM

PRINT TIME NOV. 9. 8:07PM

10-NOV-1999 12:23 FROM AUS P/L

TO

092542770

P.04/05

Page 2

Attorney's Docket No. \_\_\_\_\_

Prior U.S.A. Application(s) \_\_\_\_\_

Application No.: \_\_\_\_\_

Filing Date: \_\_\_\_\_

Status: \_\_\_\_\_

POWER OF ATTORNEY: I hereby appoint the registrants of Knobbe, Martens, Olson & Bear, LLP, 620 Newport Center Drive, Sixteenth Floor, Newport Beach, California 92660, Telephone (714) 760-0404, Customer No. 20,995, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith (if this application is assigned, I acknowledge that the appointed individuals do not represent me, and that instead they represent the assignee).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: \_\_\_\_\_

Roderick J. CHAPPEL

Inventor's signature \_\_\_\_\_

Day 5<sup>th</sup>Month MarchYear 1999

Residence (city and country): \_\_\_\_\_

Hurstbridge, Victoria, Australia

Citizenship: \_\_\_\_\_

Australian

Post Office Address: \_\_\_\_\_

11 Hillcrest Road, Hurstbridge, Victoria, 3099, Australia

Full name of second inventor: \_\_\_\_\_

Inventor's signature \_\_\_\_\_

Day \_\_\_\_\_

Month \_\_\_\_\_

Year \_\_\_\_\_

Residence (city and country): \_\_\_\_\_

Citizenship: \_\_\_\_\_

Post Office Address: \_\_\_\_\_

Full name of third inventor: \_\_\_\_\_

Inventor's signature \_\_\_\_\_

Day \_\_\_\_\_

Month \_\_\_\_\_

Year \_\_\_\_\_

Residence (city and country): \_\_\_\_\_

Citizenship: \_\_\_\_\_

Post Office Address: \_\_\_\_\_

Send Correspondence To:

KNOBBE, MARTENS, OLSON &amp; BEAR, LLP

Customer No. 20,995

KNOBBE, MARTENS, OLSON & BEAR, LLP  
620 NEWPORT CENTER DR., 16TH FLOOR, NEWPORT BEACH, CA 92660  
(714) 760-0404 FAX (714) 760-0505

RECEIVED TIME NOV. 9. 8:05PM

PRINT TIME NOV. 9. 8:07PM